GFAP	O
levels	O
are	O
already	O
used	O
as	O
a	O
marker	O
of	O
neurologic	O
damage	O
in	O
adults	O
who	O
suffer	O
strokes	other-disease
and	O
traumatic	other-disease
brain	other-disease
injuries	other-disease
.	O

A	O
number	O
of	O
conditions	O
,	O
such	O
as	O
Parkinson	other-disease
's	other-disease
disease	other-disease
,	O
are	O
thought	O
to	O
trigger	O
sleepwalking	O
in	O
people	O
without	O
a	O
previous	O
history	O
of	O
sleepwalking	O
.	O

Sabinas	other-disease
brittle	other-disease
hair	other-disease
syndrome	other-disease
,	O
also	O
called	O
Sabinas	other-disease
syndrome	other-disease
or	O
brittle	other-disease
hair-mental	other-disease
deficit	other-disease
syndrome	other-disease
,	O
is	O
an	O
autosomal	O
recessive	O
congenital	O
disorder	O
affecting	O
the	O
integumentary	O
system	O
.	O

It	O
is	O
also	O
estimated	O
that	O
there	O
are	O
30	O
million	O
thalassemia	other-disease
carriers	O
in	O
the	O
country	O
.	O

Both	O
HIT	other-disease
and	O
PNH	other-disease
require	O
particular	O
treatment	O
.	O

Acquired	other-disease
non-accommodative	other-disease
strabismus	other-disease
and	O
secondary	other-disease
strabismus	other-disease
are	O
developed	O
after	O
normal	O
binocular	O
vision	O
has	O
developed	O
.	O

Jaundice	other-disease
is	O
a	O
sign	O
indicating	O
the	O
presence	O
of	O
an	O
underlying	O
diseases	O
involving	O
abnormal	O
bilirubin	O
metabolism	O
,	O
liver	O
dysfunction	O
,	O
or	O
biliary-tract	O
obstruction	O
.	O

Suppression	O
of	O
HIV	other-disease
with	O
antiretroviral	O
medications	O
,	O
careful	O
monitoring	O
of	O
immunosuppressive	O
medications	O
are	O
important	O
means	O
of	O
prevention	O
.	O

Platelet	O
transfusions	O
are	O
not	O
routinely	O
used	O
to	O
treat	O
HIT	other-disease
because	O
thrombosis	other-disease
,	O
not	O
bleeding	O
,	O
is	O
the	O
primary	O
problem	O
.	O

BTG	O
subsequently	O
won	O
approvals	O
for	O
orphan	O
drug	O
status	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
for	O
treating	O
alcoholic	O
hepatitis	O
,	O
Turner	other-disease
syndrome	O
,	O
and	O
HIV	other-disease
-induced	O
weight	O
loss	O
.	O

In	O
the	O
US	O
,	O
the	O
incidence	O
rate	O
for	O
Morquio	other-disease
syndrome	other-disease
is	O
estimated	O
at	O
between	O
1	O
in	O
200,000	O
and	O
1	O
in	O
300,000	O
live	O
births	O
.	O

Variants	O
causing	O
a	O
reduction	O
in	O
the	O
early	O
peak	O
current	O
can	O
cause	O
Brugada	other-disease
syndrome	other-disease
and	O
cardiac	other-disease
conduction	other-disease
disease	other-disease
,	O
while	O
other	O
variants	O
have	O
been	O
associated	O
with	O
dilated	other-disease
cardiomyopathy	other-disease
.	O

Following	O
a	O
short	O
illness	O
,	O
Kilroy	O
died	O
of	O
Hodgkin	other-disease
's	other-disease
lymphoma	other-disease
on	O
Christmas	O
Day	O
1967	O
,	O
aged	O
24	O
.	O

Gouty	other-disease
arthritis	other-disease
can	O
become	O
particularly	O
painful	O
and	O
potentially	O
debilitating	O
when	O
gout	O
can	O
not	O
successfully	O
be	O
treated	O
.	O

Many	O
cases	O
of	O
spontaneous	O
abortion	O
may	O
be	O
described	O
in	O
the	O
same	O
way	O
as	O
maternal	O
transplant	O
rejection	O
,	O
and	O
a	O
chronic	O
insufficient	O
tolerance	O
may	O
cause	O
infertility	other-disease
.	O

In	O
a	O
2006	O
interview	O
,	O
Ekstein	O
said	O
that	O
while	O
four	O
of	O
his	O
first	O
five	O
children	O
died	O
of	O
Tay-Sachs	other-disease
disease	O
,	O
none	O
of	O
his	O
children	O
born	O
subsequent	O
to	O
the	O
founding	O
of	O
Dor	O
Yeshorim	O
suffered	O
the	O
condition	O
.	O

Both	O
her	O
father	O
and	O
older	O
sister	O
have	O
Ménière	other-disease
's	other-disease
disease	other-disease
as	O
well	O
.	O

Sarcoidosis	other-disease
and	O
cancer	other-disease
may	O
mimic	O
one	O
another	O
,	O
making	O
the	O
distinction	O
difficult	O
.	O

Infection	O
with	O
Human	other-disease
Immunodeficiency	other-disease
Virus	other-disease
/	O
Acquired	other-disease
immunodeficiency	other-disease
Syndrome	other-disease
(	O
AIDS	other-disease
)	O
can	O
cause	O
a	O
related	O
salivary	O
gland	O
disease	O
known	O
as	O
Diffuse	other-disease
Infiltrative	other-disease
Lymphocytosis	other-disease
Syndrome	other-disease
(	O
DILS	other-disease
)	O
.	O

Those	O
who	O
are	O
obese	O
during	O
pregnancy	O
have	O
a	O
greater	O
risk	O
of	O
have	O
a	O
child	O
with	O
a	O
number	O
of	O
congenital	O
malformations	O
including	O
:	O
neural	other-disease
tube	other-disease
defects	other-disease
such	O
as	O
anencephaly	other-disease
and	O
spina	other-disease
bifida	other-disease
,	O
cardiovascular	other-disease
anomalies	other-disease
,	O
including	O
septal	other-disease
anomalies	other-disease
,	O
cleft	other-disease
lip	other-disease
and	O
palate	other-disease
,	O
anorectal	other-disease
malformation	other-disease
,	O
limb	other-disease
reduction	other-disease
anomalies	other-disease
,	O
and	O
hydrocephaly	other-disease
.	O

Below	O
normal	O
levels	O
of	O
CD36	O
expression	O
in	O
the	O
kidneys	O
has	O
been	O
implicated	O
as	O
a	O
genetic	O
risk	O
factor	O
for	O
hypertension	other-disease
(	O
high	O
blood	O
pressure	O
)	O
.	O

In	O
molecular	other-disease
apocrine	other-disease
breast	other-disease
cancer	other-disease
(	O
ER-/AR+	other-disease
)	O
there	O
is	O
a	O
positive	O
feedback	O
loop	O
between	O
androgen	O
receptor	O
and	O
extracellular	O
signal-regulated	O
kinase	O
(	O
ERK	O
)	O
via	O
CREB1	O
which	O
can	O
be	O
inhibited	O
by	O
anti-androgens	O
.	O

Researchers	O
are	O
unable	O
to	O
predict	O
who	O
with	O
heartburn	other-disease
will	O
develop	O
Barrett	other-disease
's	other-disease
esophagus	other-disease
.	O

His	O
focus	O
on	O
subthreshold	other-disease
mood	other-disease
disorders	other-disease
enlarged	O
the	O
boundaries	O
of	O
bipolar	O
disorders	O
.	O

astrocytoma	other-disease
.	O

Xerostomia	other-disease
,	O
or	O
a	O
decrease	O
in	O
saliva	O
flow	O
,	O
can	O
be	O
a	O
side	O
effect	O
of	O
many	O
drugs	O
,	O
which	O
,	O
in	O
turn	O
,	O
can	O
lead	O
to	O
the	O
development	O
of	O
taste	O
disturbances	O
such	O
as	O
dysgeusia	O
.	O

Rotumah	O
was	O
born	O
with	O
hemiplegia	other-disease
and	O
cerebral	other-disease
palsy	other-disease
.	O

In	O
at	O
least	O
25	O
%	O
of	O
cases	O
(	O
the	O
most	O
commonly	O
occurring	O
classification	O
)	O
,	O
neurogenic	other-disease
diabetes	other-disease
insipidus	other-disease
is	O
of	O
unknown	O
cause	O
,	O
meaning	O
that	O
the	O
lack	O
of	O
vasopressin	O
production	O
arose	O
from	O
an	O
unknown	O
cause	O
.	O

Hyperkalemic	other-disease
periodic	other-disease
paralysis	other-disease
(	O
HYPP	other-disease
,	O
HyperKPP	other-disease
)	O
is	O
a	O
genetic	O
disorder	O
that	O
occurs	O
in	O
horses	O
.	O

Neuropathy	other-disease
disorders	other-disease
usually	O
have	O
onset	O
in	O
childhood	O
or	O
young	O
adulthood	O
.	O

Larger	O
amounts	O
of	O
exposure	O
can	O
cause	O
other	O
diseases	O
such	O
as	O
Hepatitis	other-disease
and	O
Jaundice	other-disease
.	O

She	O
was	O
diagnosed	O
with	O
Asperger	other-disease
Syndrome	other-disease
when	O
she	O
was	O
15	O
.	O

Other	O
features	O
include	O
a	O
single	O
(	O
simian	O
)	O
palmar	O
crease	O
,	O
long	O
,	O
slender	O
fingers	O
,	O
flat	O
feet	O
and	O
cryptorchidism	other-disease
(	O
in	O
males	O
)	O
.	O

Hypervalinemia	other-disease
,	O
is	O
a	O
rare	O
autosomal	O
recessive	O
metabolic	O
disorder	O
in	O
which	O
urinary	O
and	O
serum	O
levels	O
of	O
the	O
branched-chain	O
amino	O
acid	O
valine	O
are	O
elevated	O
,	O
without	O
related	O
elevation	O
of	O
the	O
branched-chain	O
amino	O
acids	O
leucine	O
and	O
isoleucine	O
.	O

Approximately	O
1	O
%	O
of	O
those	O
whose	O
CNS	O
is	O
affected	O
die	O
from	O
mumps	other-disease
.	O

There	O
is	O
no	O
evidence	O
that	O
fecal	other-disease
incontinence	other-disease
is	O
a	O
consequence	O
of	O
this	O
surgery	O
for	O
abscess	O
drainage	O
.	O

Besides	O
its	O
cosmetic	O
application	O
,	O
Botox	O
is	O
used	O
in	O
the	O
treatment	O
of	O
other	O
conditions	O
including	O
migraine	other-disease
headache	other-disease
and	O
cervical	other-disease
dystonia	other-disease
(	O
spasmodic	other-disease
torticollis	other-disease
)	O
(	O
a	O
neuromuscular	O
disorder	O
involving	O
the	O
head	O
and	O
neck	O
)	O
.	O

In	O
Europe	O
,	O
they	O
are	O
particularly	O
threatened	O
by	O
crayfish	other-disease
plague	other-disease
,	O
which	O
is	O
caused	O
by	O
the	O
North	O
American	O
water	O
mold	O
``	O
Aphanomyces	other-disease
astaci	other-disease
.	other-disease
``	O

The	O
unproven	O
health	O
benefits	O
attributed	O
to	O
yogurt	O
that	O
were	O
previously	O
posted	O
on	O
the	O
walls	O
of	O
Pinkberry	O
(	O
e.g.	O
,	O
cures	O
colon	other-disease
cancer	other-disease
,	O
fights	O
yeast	O
infections	O
)	O
have	O
been	O
removed	O
.	O

Necrosis	other-disease
is	O
common	O
in	O
the	O
kidney	O
and	O
spleen	O
,	O
and	O
sometimes	O
in	O
the	O
liver	O
.	O

Her	O
final	O
marriage	O
was	O
to	O
Sergei	O
Radzinsky	O
,	O
whom	O
she	O
married	O
to	O
keep	O
him	O
in	O
the	O
country	O
;	O
he	O
was	O
receiving	O
treatments	O
for	O
aplastic	other-disease
anemia	other-disease
as	O
a	O
result	O
of	O
exposure	O
to	O
Chernobyl	O
.	O

Transient	other-disease
myeloproliferative	other-disease
disease	other-disease
involves	O
the	O
excessive	O
proliferation	O
of	O
non-malignant	O
megakaryoblasts	O
.	O

SRCAP	O
encodes	O
a	O
SNF2-related	O
chromatin-remodeling	O
ATPase	O
that	O
is	O
a	O
coactivator	O
for	O
CREB-binding	O
protein	O
(	O
or	O
CBP	O
)	O
,	O
which	O
is	O
the	O
major	O
cause	O
of	O
Rubinstein–Taybi	other-disease
syndrome	O
.	O

The	O
usual	O
treatment	O
of	O
a	O
standardised	O
Adie	other-disease
syndrome	other-disease
is	O
to	O
prescribe	O
reading	O
glasses	O
to	O
correct	O
for	O
impairment	O
of	O
the	O
eye	O
(	O
s	O
)	O
.	O

Awareness	O
of	O
encephalitis	other-disease
is	O
raised	O
through	O
events	O
such	O
as	O
World	O
Encephalitis	other-disease
Day	O
which	O
was	O
founded	O
by	O
the	O
Society	O
in	O
2014	O
and	O
through	O
fundraising	O
events	O
.	O

Chronic	other-disease
wound	other-disease
pain	other-disease
is	O
described	O
as	O
acute	O
or	O
chronic	O
.	O

Through	O
to	O
the	O
navy	O
's	O
supply	O
of	O
vitamins	O
by	O
adding	O
citrus	O
to	O
their	O
rum	O
in	O
hope	O
to	O
defeat	O
scurvy	other-disease
,	O
he	O
amongst	O
other	O
had	O
acquired	O
a	O
taste	O
for	O
citrus	O
.	O

DIOS	other-disease
tends	O
to	O
occur	O
in	O
older	O
individuals	O
with	O
pancreatic	O
insufficiency	O
.	O

Other	O
studies	O
demonstrate	O
differential	O
expression	O
of	O
Papillary	other-disease
Thyroid	other-disease
cancer	O
and	O
Estrogen	O
Receptor	O
alpha-silenced	O
MCF7	O
breast	O
cancer	O
cells	O
.	O

Various	O
diagnostic	O
frameworks	O
for	O
CHS	other-disease
have	O
been	O
proposed	O
.	O

When	O
Cowden	other-disease
syndrome	other-disease
and	O
Cowden-like	other-disease
syndrome	other-disease
are	O
caused	O
by	O
SDHD	O
gene	O
mutations	O
,	O
the	O
conditions	O
are	O
associated	O
with	O
a	O
particularly	O
high	O
risk	O
of	O
developing	O
breast	O
and	O
thyroid	other-disease
cancers	other-disease
.	O

Hemoglobin	O
A2	O
may	O
be	O
increased	O
in	O
beta	other-disease
thalassemia	other-disease
or	O
in	O
people	O
who	O
are	O
heterozygous	O
for	O
the	O
beta	O
thalassemia	O
gene	O
.	O

The	O
potassium	other-disease
deficiency	other-disease
may	O
also	O
be	O
a	O
result	O
of	O
the	O
Chinese	O
diet	O
or	O
genetic	O
predisposition	O
.	O

His	O
clinical	O
sub-specialties	O
are	O
vitreoretinal	O
surgery	O
,	O
retinal	other-disease
vascular	other-disease
disease	other-disease
,	O
diabetic	other-disease
retinopathy	other-disease
and	O
macular	O
degeneration	O

On	O
,	O
food	O
contaminated	O
with	O
cholera	other-disease
was	O
distributed	O
to	O
the	O
passengers	O
on	O
Aerolíneas	O
Argentinas	O
Flight	O
386	O
,	O
sometimes	O
referred	O
to	O
as	O
the	O
``	O
Valentine	O
's	O
Day	O
flight	O
''	O
.	O

Autoimmune	other-disease
variants	other-disease
peripheral	other-disease
neuropathies	other-disease
or	O
progressive	other-disease
inflammatory	other-disease
neuropathy	other-disease
could	O
be	O
in	O
the	O
list	O
assuming	O
the	O
autoimmune	O
model	O
for	O
MS	other-disease
,	O
together	O
with	O
a	O
rare	O
demyelinating	other-disease
lesional	other-disease
variant	other-disease
of	other-disease
trigeminal	other-disease
neuralgia	other-disease
and	O
some	O
NMDAR	O
Anti-NMDA	O
receptor	O
encephalitis	O

Cardiomyopathy	other-disease
and	O
muscular	other-disease
dystrophy	other-disease
may	O
occur	O
rarely	O
.	O

Hayden	O
's	O
research	O
focus	O
is	O
primarily	O
on	O
genetic	O
diseases	O
,	O
including	O
genetics	other-disease
of	other-disease
[	other-disease
lipoprotein	other-disease
]	other-disease
disorders	other-disease
,	O
Huntington	other-disease
disease	other-disease
,	O
predictive	O
medicine	O
,	O
personalized	O
medicine	O
and	O
drug	O
development	O
.	O

Prince	O
Heinrich	O
of	O
Prussia	O
(	O
;	O
9	O
January	O
1900	O
–	O
26	O
February	O
1904	O
)	O
,	O
was	O
the	O
haemophiliac	other-disease
third	O
son	O
and	O
youngest	O
child	O
of	O
Prince	O
Henry	O
of	O
Prussia	O
and	O
Princess	O
Irene	O
of	O
Hesse	O
and	O
by	O
Rhine	O
,	O
and	O
thus	O
a	O
grandson	O
of	O
Frederick	O
III	O
,	O
German	O
Emperor	O
on	O
his	O
father	O
's	O
side	O
and	O
a	O
great-grandson	O
of	O
Queen	O
Victoria	O
through	O
both	O
his	O
mother	O
and	O
father	O
.	O

It	O
is	O
implicated	O
in	O
neurotoxicity	O
associated	O
with	O
stroke	other-disease
and	O
neurodegenerative	O
diseases	O
,	O
neural	O
regulation	O
of	O
smooth	O
muscle	O
,	O
including	O
peristalsis	O
,	O
and	O
penile	O
erection	O
.	O

He	O
discovered	O
that	O
in	O
the	O
direct	O
radiograms	O
and	O
in	O
the	O
urographic	O
images	O
,	O
you	O
can	O
identify	O
determining	O
elements	O
for	O
a	O
differential	O
diagnosis	O
with	O
the	O
Wilms	other-disease
'	other-disease
tumor	other-disease
.	O

Men	O
who	O
present	O
with	O
this	O
complaint	O
may	O
have	O
Koro	other-disease
,	O
but	O
they	O
may	O
also	O
be	O
misinformed	O
about	O
normal	O
genital	O
size	O
.	O

Other	O
conditions	O
associated	O
with	O
this	O
condition	O
include	O
acanthosis	other-disease
nigricans	other-disease
,	O
fatty	other-disease
liver	other-disease
,	O
hypertriglyceridemia	other-disease
and	O
polycystic	other-disease
ovary	other-disease
syndrome	other-disease
in	O
women	O
.	O

Her	O
work	O
showing	O
that	O
the	O
greatest	O
risk	O
factor	O
for	O
meningococcal	other-disease
disease	O
is	O
crowding	O
led	O
directly	O
to	O
changes	O
in	O
how	O
state	O
homes	O
are	O
built	O
.	O

The	O
crystallization	O
of	O
uric	O
acid	O
,	O
often	O
related	O
to	O
relatively	O
high	O
levels	O
in	O
the	O
blood	O
,	O
is	O
the	O
underlying	O
cause	O
of	O
gout	other-disease
.	O

Shown	O
to	O
suffer	O
from	O
Reye	other-disease
's	other-disease
syndrome	other-disease
in	O
infancy	O
,	O
as	O
well	O
as	O
anorexia	other-disease
nervosa	other-disease
later	O
in	O
life	O
,	O
she	O
overcomes	O
both	O
with	O
the	O
significant	O
aid	O
of	O
her	O
family	O
.	O

In	O
Peru	O
today	O
,	O
HIV	other-disease
infections	other-disease
are	O
concentrated	O
among	O
many	O
low-income	O
Peruvian	O
men	O
who	O
have	O
engaged	O
in	O
same-sex	O
sexual	O
contact	O
.	O

While	O
SNRIs	O
have	O
similar	O
efficacy	O
as	O
SSRIs	O
,	O
many	O
psychiatrists	O
prefer	O
to	O
use	O
SSRIs	O
first	O
in	O
the	O
treatment	O
of	O
Generalized	other-disease
Anxiety	other-disease
Disorder	other-disease
.	O

PNH	other-disease
increases	O
the	O
risk	O
of	O
venous	other-disease
thrombosis	other-disease
but	O
is	O
also	O
associated	O
with	O
hemolytic	other-disease
anemia	other-disease
(	O
anemia	other-disease
resulting	O
from	O
destruction	O
of	O
red	O
blood	O
cells	O
)	O
.	O

Butternut	O
squash	O
seeds	O
have	O
been	O
cited	O
for	O
reducing	O
social	other-disease
anxiety	other-disease
disorder	other-disease
within	O
an	O
hour	O
of	O
consumption	O
in	O
a	O
double-blind	O
trial	O
.	O

When	O
Jane	O
Winiberg	O
saw	O
a	O
progeria	other-disease
television	O
special	O
,	O
she	O
and	O
Mark	O
Street	O
wrote	O
a	O
song	O
about	O
Okines	O
and	O
other	O
children	O
.	O

Ectrodactyly	other-disease
can	O
be	O
caused	O
by	O
various	O
changes	O
to	O
7q	O
.	O

Debate	O
exists	O
as	O
to	O
whether	O
this	O
is	O
a	O
result	O
of	O
male	other-disease
dwarfism	other-disease
or	O
female	other-disease
gigantism	other-disease
.	O

Cyclothymia	other-disease
is	O
also	O
often	O
confused	O
with	O
borderline	other-disease
personality	other-disease
disorder	O
due	O
to	O
their	O
similar	O
symptoms	O
,	O
especially	O
in	O
older	O
adolescents	O
and	O
young	O
adults	O
.	O

Rocky	other-disease
Mountain	other-disease
spotted	other-disease
fever	other-disease
can	O
be	O
a	O
very	O
severe	O
illness	O
and	O
patients	O
often	O
require	O
hospitalization	O
.	O

They	O
include	O
depressions	other-disease
due	O
to	O
physical	O
illness	O
,	O
medications	O
,	O
and	O
substance	O
abuse	O
.	O

Study	O
has	O
collected	O
wide-ranging	O
data	O
and	O
has	O
focused	O
on	O
risk	O
factors	O
that	O
predict	O
vascular	other-disease
disease	other-disease
,	O
diabetes	other-disease
,	O
cognitive	other-disease
impairmen	other-disease
t	O
and	O
dementia	other-disease
—	O
and	O
the	O
benefits	O
of	O
living	O
a	O
healthy	O
lifestyle	O
.	O

Aseptic	O
meningitis	O
is	O
caused	O
by	O
viruses	other-disease
,	O
mycobacteria	other-disease
,	O
spirochetes	other-disease
,	O
fungi	O
,	O
medications	O
,	O
and	O
cancer	other-disease
malignancies	other-disease
.	O

Dr	O
.	O
Edward	O
D.	O
Miller	O
,	O
dean	O
of	O
the	O
medical	O
faculty	O
and	O
CEO	O
of	O
Johns	O
Hopkins	O
Medicine	O
,	O
said	O
that	O
Yardley	O
was	O
``	O
one	O
of	O
the	O
founding	O
fathers	O
of	O
the	O
field	O
of	O
gastrointestinal	O
pathology	O
,	O
''	O
adding	O
that	O
he	O
made	O
``	O
groundbreaking	O
observations	O
on	O
Whipple	other-disease
's	other-disease
disease	other-disease
of	O
the	O
gastrointestinal	O
tract	O
and	O
helped	O
define	O
the	O
current	O
classification	O
system	O
for	O
neoplastic	other-disease
dysplasia	other-disease
in	O
the	O
colon	other-disease
and	O
esophagus	other-disease
.	O
''	O

She	O
was	O
described	O
as	O
physically	O
unattractive	O
and	O
was	O
(	O
by	O
the	O
standard	O
of	O
medicine	O
of	O
that	O
time	O
)	O
infertile	O
from	O
Basedow	other-disease
syndrome	other-disease
.	O

As	O
malakoplakia	other-disease
is	O
a	O
condition	O
associated	O
with	O
chronic	other-disease
cystitis	other-disease
,	O
it	O
usually	O
presents	O
itself	O
as	O
a	O
cystitis	other-disease
condition	O
.	O

Some	O
examples	O
of	O
behavioral	O
disorders	O
include	O
anxiety	other-disease
,	O
alcohol	other-disease
dependence	other-disease
,	O
and	O
drug	O
use	O
.	O

Dysrhythmias	O
and	O
sudden	O
cardiac	O
death	O
(	O
SCD	other-disease
)	O
was	O
shown	O
to	O
occur	O
even	O
before	O
the	O
manifestation	O
of	O
DCM	other-disease
and	O
heart	O
failure	O
symptoms	O
in	O
LMNA	other-disease
mutation	O
carriers	O
.	O

The	O
Austrian	O
Federal	O
Railways	O
puts	O
a	O
quarter	O
of	O
its	O
staff	O
(	O
10,000	O
workers	O
)	O
on	O
short-time	O
work	O
in	O
response	O
to	O
the	O
coronavirus	other-disease
pandemic	O
.	O

Morpheaform	other-disease
sarcoidosis	other-disease
is	O
a	O
very	O
rare	O
cutaneous	O
condition	O
characterized	O
by	O
specific	O
cutaneous	O
skin	O
lesions	O
of	O
sarcoidosis	O
accompanied	O
by	O
substantial	O
fibrosis	O
,	O
simulating	O
morphea	O
.	O

Rheumatic	other-disease
fever	other-disease
is	O
common	O
worldwide	O
and	O
responsible	O
for	O
many	O
cases	O
of	O
damaged	O
heart	O
valves	O
.	O

Two	O
of	O
the	O
group	O
subsequently	O
tested	O
positive	O
for	O
COVID-19	other-disease
and	O
the	O
eight	O
players	O
were	O
put	O
into	O
self-isolation	O
.	O

However	O
,	O
subsequent	O
studies	O
found	O
significant	O
clinical	O
,	O
pathologic	O
,	O
and	O
pathophysiological	O
differences	O
between	O
these	O
two	O
types	O
of	O
lymphoma	other-disease
.	O

Wani	O
was	O
diagnosed	O
with	O
Rokitansky	other-disease
Syndrome	other-disease
at	O
the	O
age	O
of	O
18	O
;	O
a	O
congenital	O
disorder	O
that	O
happens	O
to	O
one	O
in	O
every	O
4,500	O
to	O
5,000	O
women	O
.	O

Other	O
inherited	O
causes	O
of	O
left	O
ventricular	O
hypertrophy	O
may	O
include	O
Fabry	other-disease
disease	O
,	O
Friedreich	other-disease
's	other-disease
ataxia	other-disease
,	O
and	O
certain	O
medications	O
such	O
as	O
tacrolimus	O
.	O

Described	O
as	O
an	O
``	O
instantly	O
recognizable	O
sad-faced	O
actor	O
''	O
,	O
Schiavelli	O
was	O
diagnosed	O
with	O
Marfan	other-disease
syndrome	other-disease
in	O
childhood	O
.	O

Several	O
studies	O
have	O
outlined	O
the	O
importance	O
of	O
autocrine	O
IL-6	O
signaling	O
in	O
lung	other-disease
and	other-disease
breast	other-disease
cancers	other-disease
.	O

This	O
causes	O
several	O
adverse	O
effects	O
,	O
including	O
hypotension	other-disease
and	O
cyanosis	other-disease
.	O

There	O
are	O
mainly	O
three	O
types	O
of	O
anterior	other-disease
pituitary	other-disease
tumors	other-disease
and	O
their	O
associated	O
disorders	O
.	O

Nitrogen	other-disease
narcosis	other-disease
is	O
a	O
hazard	O
when	O
diving	O
.	O

For	O
example	O
,	O
acromegaly	other-disease
results	O
from	O
excessive	O
secretion	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
often	O
being	O
released	O
by	O
a	O
pituitary	O
adenoma	O
.	O

95	O
%	O
of	O
Celiac	other-disease
Disease	other-disease
patients	O
are	O
positive	O
for	O
DQ2	other-disease
or	O
DQ8	other-disease
.	O

Yellow	other-disease
Fever	other-disease
is	O
transmitted	O
by	O
mosquitoes	O
,	O
when	O
it	O
bites	O
an	O
infected	O
person	O
it	O
carries	O
several	O
thousand	O
infective	O
doses	O
of	O
the	O
disease	O
making	O
it	O
a	O
carrier	O
for	O
life	O
passing	O
it	O
from	O
human	O
to	O
human	O
.	O

Gestational	other-disease
(	other-disease
incidental	other-disease
)	other-disease
thrombocytopenia	other-disease
is	O
a	O
condition	O
that	O
commonly	O
affects	O
pregnant	O
women	O
.	O

Proceeds	O
from	O
the	O
song	O
's	O
went	O
to	O
Sanfilippo	O
Children	O
's	O
Foundation	O
,	O
a	O
not-for-profit	O
charity	O
that	O
dedicates	O
their	O
resources	O
to	O
progressing	O
clinical	O
research	O
into	O
the	O
effective	O
treatment	O
of	O
Mucopolysaccharidosis	other-disease
III	other-disease
,	other-disease
also	O
known	O
as	O
MPSIII	other-disease
or	O
Sanfilippo	O
Syndrome	O
.	O

Glaucoma	other-disease
is	O
a	O
type	O
of	O
blindness	O
that	O
begins	O
at	O
the	O
edge	O
of	O
the	O
visual	O
field	O
and	O
progresses	O
inward	O
.	O

It	O
reached	O
phase	O
II	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
depression	other-disease
,	O
erectile	other-disease
dysfunction	other-disease
,	O
and	O
premature	other-disease
ejaculation	other-disease
prior	O
to	O
the	O
discontinuation	O
of	O
its	O
development	O
.	O

Loss	O
of	O
cancer	O
suppressor	O
genes	O
,	O
early	O
in	O
prostatic	other-disease
carcinogenesis	other-disease
,	O
have	O
been	O
localized	O
to	O
chromosomes	O
''	O
8p	O
``	O
,	O
``	O
10q	O
``	O
,	O
``	O
13q	O
``	O
,	O
and	O
``	O
16q	O
``	O
.	O

The	O
following	O
table	O
shows	O
the	O
risk	O
of	O
development	O
of	O
DIL	other-disease
of	O
some	O
of	O
these	O
drugs	O
on	O
a	O
high	O
to	O
very	O
low	O
scale	O
.	O

The	O
effects	O
of	O
smallpox	other-disease
on	O
the	O
Inca	O
empire	O
were	O
even	O
more	O
devastating	O
.	O

Cyclothymia	other-disease
is	O
often	O
not	O
recognized	O
by	O
the	O
affected	O
individual	O
or	O
medical	O
professionals	O
due	O
to	O
its	O
ostensibly	O
mild	O
symptoms	O
.	O

He	O
died	O
from	O
complications	O
of	O
Creutzfeldt–Jakob	other-disease
disease	other-disease
on	O
May	O
19	O
,	O
2018	O
in	O
Bakersfield	O
,	O
California	O
.	O

They	O
are	O
unique	O
in	O
being	O
the	O
only	O
organisation	O
specialising	O
in	O
support	O
for	O
bipolar	other-disease
disorder	other-disease
and	O
are	O
one	O
of	O
the	O
largest	O
user-led	O
organisations	O
in	O
the	O
mental	O
health	O
sector	O
,	O
with	O
5,000	O
members	O
.	O

Clinical	O
manifestations	O
of	O
this	O
deficiency	O
can	O
include	O
myopathy	other-disease
,	O
cardiomyopathy	other-disease
,	O
episodes	O
of	O
coma	other-disease
,	O
and	O
hypoglycemia	other-disease
.	O

Mutism	other-disease
may	O
be	O
partial	O
and	O
patients	O
may	O
repeat	O
meaningless	O
phrases	O
(	O
verbigeration	O
)	O
or	O
speak	O
only	O
to	O
repeat	O
what	O
someone	O
else	O
says	O
(	O
echolalia	O
)	O
.	O

Type	other-disease
2	other-disease
(	O
Dunnigan	O
Variety	O
,	O
FPL2	other-disease
)	O
is	O
the	O
most	O
common	O
form	O
and	O
is	O
due	O
to	O
mutations	O
in	O
the	O
LMNA	O
gene	O
.	O

hypertrophy	other-disease
of	other-disease
the	other-disease
retinal	other-disease
pigment	other-disease
epithelium	other-disease
(	O
CHRPE	other-disease
)	O
,	O
in	O
addition	O
to	O
multiple	O
adenomatous	other-disease
polyps	other-disease
of	other-disease
the	other-disease
colon	other-disease
.	O

Scurvy	other-disease
,	O
a	O
disease	O
that	O
develops	O
from	O
an	O
extended	O
shortage	O
of	O
Vitamin	O
C	O
,	O
has	O
previously	O
been	O
found	O
prevalent	O
in	O
certain	O
South	O
African	O
mining	O
populations	O
.	O

The	O
cranial	other-disease
dysmorphisms	other-disease
associated	O
with	O
3C	other-disease
syndrome	other-disease
are	O
heterogeneous	O
and	O
include	O
a	O
degree	O
of	O
macrocephaly	O
,	O
a	O
large	O
anterior	O
fontanel	O
,	O
a	O
particularly	O
prominent	O
occiput	O
and	O
forehead	O
,	O
ocular	other-disease
hypertelorism	other-disease
(	O
wide-set	O
eyes	O
)	O
,	O
slanted	other-disease
palpebral	other-disease
fissures	other-disease
,	O
cleft	other-disease
palate	other-disease
,	O
a	O
depressed	O
nasal	O
bridge	O
,	O
cleft	O
palate	O
with	O
associated	O
bifid	O
uvula	O
,	O
low-set	O
ears	O
,	O
micrognathia	other-disease
(	O
an	O
abnormally	O
small	O
jaw	O
)	O
,	O
brachycephaly	other-disease
(	O
flattened	O
head	O
)	O
,	O
and	O
ocular	other-disease
coloboma	other-disease
.	O

At	O
autopsy	O
pineal	other-disease
hyperplasia	other-disease
was	O
found	O
in	O
all	O
three	O
.	O

Sudden	other-disease
cardiac	other-disease
death	other-disease
,	O
either	O
due	O
to	O
ventricular	O
arrhythmias	O
or	O
complete	O
heart	O
block	O
is	O
a	O
rare	O
complication	other-disease
of	other-disease
cardiac	other-disease
sarcoidosis	other-disease
.	O

Attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
is	O
known	O
to	O
be	O
highly	O
comorbid	O
with	O
conduct	O
disorder	O
(	O
a	O
theorized	O
precursor	O
to	O
ASPD	other-disease
)	O
,	O
and	O
may	O
also	O
co-occur	O
with	O
psychopathic	O
tendencies	O
.	O

Insomnia	other-disease
may	O
increase	O
racing	O
thoughts	O
and	O
those	O
effected	O
will	O
find	O
sleep	O
apnea	O
treatment	O
and	O
nasal	O
surgery	O
helpful	O
to	O
eliminate	O
their	O
racing	O
thoughts	O
.	O

Stella	O
had	O
a	O
brother	O
,	O
John	O
,	O
who	O
had	O
Down	other-disease
syndrome	other-disease
.	O

However	O
,	O
the	O
event	O
was	O
postponed	O
for	O
2021	O
along	O
with	O
the	O
Summer	O
Olympics	O
due	O
to	O
the	O
COVID-19	other-disease
pandemic	O
,	O
leaving	O
all	O
the	O
qualifiers	O
unable	O
to	O
compete	O
.	O

Founder	O
and	O
President	O
of	O
Ritter	O
Pharmaceuticals	O
,	O
Andrew	O
Ritter	O
,	O
suffered	O
from	O
severe	O
lactose	other-disease
intolerance	other-disease
since	O
his	O
early	O
childhood	O
.	O

The	O
ASC	O
with	O
the	O
provincial	O
Alzheimer	other-disease
Societies	O
and	O
the	O
local	O
Alzheimer	other-disease
Societies	O
are	O
registered	O
as	O
separate	O
charities	O
and	O
operate	O
in	O
cooperation	O
using	O
a	O
federated	O
model	O
.	O

The	O
blepharospasm	other-disease
referred	O
to	O
here	O
is	O
officially	O
called	O
benign	other-disease
essential	other-disease
blepharospasm	other-disease
(	O
BEB	other-disease
)	O
to	O
distinguish	O
it	O
from	O
the	O
less	O
serious	O
secondary	O
blinking	O
disorders	O
.	O

There	O
is	O
currently	O
no	O
known	O
treatment	O
or	O
cure	O
for	O
most	O
(	O
or	O
perhaps	O
all	O
)	O
causes	O
of	O
hypotonia	other-disease
,	O
and	O
objective	O
manifestations	O
can	O
be	O
lifelong	O
.	O

These	O
are	O
:	O
thrombocytopenia	other-disease
,	O
the	O
presence	O
of	O
candidal	other-disease
dermatitis	other-disease
,	O
the	O
use	O
of	O
systemic	O
steroids	O
,	O
birth	O
weights	O
of	O
&	O
lt	O
;	O
1,000	O
g	O
,	O
presence	O
of	O
a	O
central	O
catheter	O
,	O
postponing	O
enteral	O
feeding	O
,	O
vaginal	O
delivery	O
,	O
and	O
the	O
amount	O
of	O
time	O
broad-spectrum	O
antibiotics	O
were	O
given	O
.	O

However	O
,	O
basic	O
science	O
research	O
showed	O
that	O
many	O
cytokines	O
were	O
elevated	O
in	O
both	O
Crohn	other-disease
's	other-disease
disease	other-disease
and	O
ulcerative	other-disease
colitis	other-disease
.	O

Fungal	other-disease
sinusitis	other-disease
is	O
the	O
inflammation	O
of	O
the	O
lining	O
mucosa	O
of	O
the	O
paranasal	O
sinuses	O
due	O
to	O
fungal	O
infection	O
.	O

Migraine	other-disease
is	O
a	O
complex	O
disease	O
which	O
affects	O
about	O
15	O
%	O
of	O
the	O
population	O
and	O
can	O
be	O
highly	O
disabling	O
.	O

Paralysis	other-disease
of	other-disease
respiratory	other-disease
muscles	other-disease
will	O
lead	O
to	O
death	O
in	O
a	O
considerably	O
shorter	O
time	O
.	O

Chronic	other-disease
kidney	other-disease
disease	other-disease
affected	O
753	O
million	O
people	O
globally	O
in	O
2016	O
:	O
417	O
million	O
females	O
and	O
336	O
million	O
males	O
.	O

With	O
a	O
COPD	other-disease
prevalence	O
of	O
more	O
than	O
12	O
million	O
(	O
possibly	O
24	O
million	O
including	O
undiagnosed	O
ones	O
)	O
in	O
the	O
United	O
States	O
,	O
there	O
are	O
at	O
least	O
30	O
million	O
incidences	O
of	O
AECB	other-disease
annually	O
in	O
the	O
US	O
.	O

On	O
March	O
26	O
,	O
2020	O
,	O
he	O
lost	O
his	O
twelve-year	O
struggle	O
against	O
Amyotrophic	other-disease
Lateral	other-disease
Sclerosis	other-disease
at	O
the	O
age	O
of	O
57	O
.	O

A	O
1998	O
MRI	O
study	O
of	O
nine	O
climbers	O
with	O
HACE	other-disease
clearly	O
demonstrated	O
vasogenic	O
edema	O
.	O

Homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
3-phosphoglycerate	O
dehydrogenase	O
(	O
PHGDH	O
)	O
cause	O
Neu-Laxova	other-disease
syndrome	other-disease
and	O
phosphoglycerate	other-disease
dehydrogenase	other-disease
deficiency	other-disease
.	O

She	O
continued	O
to	O
study	O
the	O
vascular	O
biology	O
of	O
HIV	other-disease
infection	O
and	O
the	O
effects	O
of	O
HIV	other-disease
infection	O
on	O
the	O
central	O
nervous	O
system	O
.	O

An	O
extreme	O
case	O
of	O
hypohydrosis	other-disease
in	O
which	O
there	O
is	O
a	O
complete	O
absence	O
of	O
sweating	O
and	O
the	O
skin	O
is	O
dry	O
is	O
termed	O
anhidrosis	O
.	O

If	O
arrhythmia	other-disease
persists	O
despite	O
the	O
treatment	O
of	O
underlying	O
medical	O
conditions	O
it	O
may	O
be	O
worth	O
checking	O
a	O
complete	O
blood	O
count	O
and	O
serum	O
chemistry	O
for	O
signs	O
of	O
infection	other-disease
,	O
anemia	other-disease
,	O
or	O
electrolyte	other-disease
abnormalities	other-disease
such	O
as	O
hypokalemia	other-disease
and	O
hypomagnesemia	other-disease
.	O

He	O
felt	O
he	O
lacked	O
expertise	O
in	O
rheumatic	other-disease
diseases	other-disease
and	O
determined	O
to	O
teach	O
himself	O
.	O

Two	O
days	O
later	O
,	O
Dr	O
.	O
Wilmer	O
Krusen	O
concluded	O
that	O
the	O
Spanish	other-disease
flu	other-disease
was	O
now	O
present	O
in	O
the	O
civilian	O
population	O
.	O

Parts	O
of	O
Southern	O
India	O
and	O
most	O
of	O
Hyderabad	O
were	O
greatly	O
affected	O
by	O
the	O
Bubonic	other-disease
plague	other-disease
epidemic	other-disease
at	O
the	O
turn	O
of	O
the	O
19th	O
century	O
.	O

An	O
individual	O
displaying	O
MERRFs	other-disease
syndrome	O
will	O
manifest	O
not	O
only	O
a	O
single	O
symptom	O
,	O
but	O
patients	O
regularly	O
display	O
more	O
than	O
one	O
affected	O
body	O
part	O
at	O
a	O
time	O
.	O

This	O
abnormal	O
protein	O
builds	O
up	O
in	O
the	O
brain	O
and	O
destroys	O
nerve	O
cells	O
,	O
resulting	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
prion	other-disease
disease	other-disease
.	O

If	O
rheumatoid	other-disease
arthritis	other-disease
is	O
present	O
and	O
other	O
symptoms	O
occur	O
that	O
are	O
not	O
commonly	O
found	O
within	O
RA	O
itself	O
,	O
such	O
as	O
a	O
palpable	O
spleen	O
,	O
further	O
testing	O
should	O
be	O
done	O
.	O

Signature	O
9	O
has	O
been	O
identified	O
in	O
chronic	other-disease
lymphocytic	other-disease
leukemia	other-disease
and	O
malignant	other-disease
B-cell	other-disease
lymphoma	other-disease
and	O
feature	O
enrichment	O
for	O
T	O
&	O
gt	O
;	O
G	O
transversion	O
events	O
.	O

Enlargement	O
of	O
the	O
vestibular	O
aqueduct	O
to	O
greater	O
than	O
2	O
mm	O
is	O
associated	O
with	O
enlarged	other-disease
vestibular	other-disease
aqueduct	other-disease
syndrome	other-disease
,	O
a	O
disease	O
entity	O
that	O
is	O
associated	O
with	O
one-sided	O
hearing	O
loss	O
in	O
children	O
.	O

Subsequently	O
he	O
established	O
chronic	other-disease
depressions	other-disease
as	O
treatable	O
mood	O
disorders	O
.	O

Safe	O
blood	O
plays	O
a	O
life	O
saving	O
role	O
in	O
Thalassemia	other-disease
patients	O
who	O
need	O
blood	O
at	O
regular	O
intervals	O
.	O

Barber-Say	other-disease
syndrome	other-disease
(	O
BSS	other-disease
)	O
is	O
a	O
very	O
rare	O
congenital	O
disorder	O
associated	O
with	O
excessive	other-disease
hair	other-disease
growth	other-disease
(	O
hypertrichosis	other-disease
)	O
,	O
fragile	other-disease
(	other-disease
atrophic	other-disease
)	other-disease
skin	other-disease
,	O
eyelid	other-disease
deformities	other-disease
(	O
ectropion	other-disease
)	O
,	O
and	O
an	O
overly	other-disease
broad	other-disease
mouth	other-disease
(	O
macrostomia	other-disease
)	O
.	O

They	O
also	O
reviewed	O
recent	O
studies	O
investigating	O
genotype-phenotype	O
associations	O
in	O
DCM	other-disease
patients	O
with	O
titin	O
(	O
TTN	O
)	O
mutations	O
.	O

On	O
August	O
31	O
,	O
the	O
2020	O
US	O
Open	O
(	O
tennis	O
)	O
kicked	O
off	O
with	O
various	O
safety	O
precautions	O
and	O
void	O
of	O
spectators	O
due	O
to	O
COVID-19	other-disease
,	O
for	O
the	O
first	O
time	O
in	O
the	O
tournament	O
's	O
history	O
.	O

Review	O
of	O
the	O
literature	O
indicates	O
that	O
around	O
50-70	O
%	O
of	O
patients	O
have	O
urinary	other-disease
retention	other-disease
(	O
CES-R	other-disease
)	O
on	O
presentation	O
with	O
30-50	O
%	O
having	O
an	O
incomplete	other-disease
syndrome	other-disease
(	O
CES-I	other-disease
)	O
.	O

Bloom	other-disease
syndrome	other-disease
shares	O
some	O
features	O
with	O
Fanconi	other-disease
anemia	other-disease
possibly	O
because	O
there	O
is	O
overlap	O
in	O
the	O
function	O
of	O
the	O
proteins	O
mutated	O
in	O
this	O
related	O
disorder	O
.	O

In	O
2000	O
,	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
listed	O
91	O
countries	O
in	O
which	O
Hansen	other-disease
's	other-disease
disease	other-disease
is	O
endemic	O
.	O

It	O
is	O
more	O
effective	O
where	O
symptoms	O
of	O
catatonia	other-disease
are	O
present	O
,	O
and	O
is	O
recommended	O
for	O
use	O
under	O
NICE	O
guidelines	O
in	O
the	O
UK	O
for	O
catatonia	other-disease
if	O
previously	O
effective	O
,	O
though	O
there	O
is	O
no	O
recommendation	O
for	O
use	O
for	O
schizophrenia	other-disease
otherwise	O
.	O

There	O
are	O
also	O
many	O
pediatric	O
liver	O
diseases	O
,	O
including	O
biliary	other-disease
atresia	other-disease
,	O
alpha-1	other-disease
antitrypsin	other-disease
deficiency	other-disease
,	O
alagille	other-disease
syndrome	other-disease
,	O
progressive	other-disease
familial	other-disease
intrahepatic	other-disease
cholestasis	other-disease
,	O
Langerhans	other-disease
cell	other-disease
histiocytosis	other-disease
and	O
hepatic	other-disease
hemangioma	other-disease
a	O
benign	O
tumour	O
the	O
most	O
common	O
type	O
of	O
liver	O
tumour	O
,	O
thought	O
to	O
be	O
congenital	O
.	O

As	O
MS	other-disease
is	O
an	O
active	O
field	O
for	O
research	O
,	O
the	O
list	O
of	O
auto-antibodies	O
is	O
not	O
closed	O
nor	O
definitive	O
.	O

Tetralogy	other-disease
of	other-disease
Fallot	other-disease
with	other-disease
pulmonary	other-disease
atresia	other-disease
(	O
``	O
pseudotruncus	other-disease
arteriosus	other-disease
``	O
)	O
is	O
a	O
severe	O
variant	O
in	O
which	O
there	O
is	O
complete	O
obstruction	O
(	O
atresia	O
)	O
of	O
the	O
right	O
ventricular	O
outflow	O
tract	O
,	O
causing	O
an	O
absence	O
of	O
the	O
pulmonary	O
trunk	O
during	O
embryonic	O
development	O
.	O

Mesangial	other-disease
proliferative	other-disease
glomerulonephritis	other-disease
is	O
a	O
form	O
of	O
glomerulonephritis	other-disease
associated	O
primarily	O
with	O
the	O
mesangium	O
.	O

Symptoms	O
of	O
hypokalemia	other-disease
include	O
fatigue	O
,	O
muscular	O
weakness	O
,	O
and	O
increased	O
urine	O
production	O
.	O

The	O
United	O
States	O
has	O
the	O
highest	O
mortality	O
rate	O
among	O
patients	O
with	O
ESRD	other-disease
.	O

A	O
particular	O
group	O
of	O
physical	O
features	O
,	O
called	O
the	O
Pierre	other-disease
Robin	other-disease
sequence	O
,	O
is	O
common	O
in	O
children	O
with	O
Stickler	other-disease
syndrome	O
.	O

He	O
was	O
speaker	O
of	O
the	O
New	O
Hampshire	O
House	O
of	O
Representatives	O
for	O
one	O
week	O
before	O
he	O
died	O
from	O
COVID-19	other-disease
.	O

A	O
classic	O
symptom	O
of	O
polycythemia	other-disease
vera	other-disease
(	O
and	O
the	O
related	O
myeloproliferative	O
disease	O
essential	other-disease
thrombocythemia	other-disease
)	O
is	O
erythromelalgia	other-disease
.	O

Infectious	O
diseases	O
causing	O
ILI	other-disease
include	O
RSV	other-disease
,	O
malaria	other-disease
,	O
acute	O
HIV	other-disease
/	O
AIDS	other-disease
infection	O
,	O
herpes	other-disease
,	O
hepatitis	other-disease
C	other-disease
,	O
Lyme	other-disease
disease	other-disease
,	O
rabies	other-disease
,	O
myocarditis	other-disease
,	O
Q	other-disease
fever	other-disease
,	O
dengue	other-disease
fever	other-disease
,	O
poliomyelitis	other-disease
,	O
pneumonia	other-disease
,	O
measles	other-disease
,	O
SARS	other-disease
,	O
COVID-19	other-disease
,	O
and	O
many	O
others	O
.	O

‌Five	O
years	O
earlier	O
,	O
Claude	O
had	O
been	O
introduced	O
to	O
a	O
'	O
Father	O
Forget	O
'	O
,	O
a	O
former	O
minister	O
of	O
the	O
Reformed	O
Church	O
of	O
France	O
who	O
claimed	O
to	O
be	O
able	O
to	O
cure	O
her	O
Parkinson	other-disease
's	O
disease	O
through	O
communal	O
prayer	O
.	O

PTCH1	O
has	O
homology	O
to	O
Niemann-Pick	other-disease
disease	other-disease
,	O
type	O
C1	O
(	O
NPC1	O
)	O
that	O
is	O
known	O
to	O
transport	O
lipophilic	O
molecules	O
across	O
a	O
membrane	O
.	O

Along	O
with	O
other	O
misfortunes	O
in	O
the	O
1920s	O
,	O
foot-and-mouth	other-disease
disease	other-disease
struck	O
in	O
1926	O
.	O

Gardner	other-disease
syndrome	other-disease
is	O
also	O
associated	O
with	O
familial	other-disease
adenomatous	other-disease
polyposis	other-disease
and	O
may	O
manifest	O
as	O
aggressive	other-disease
fibromatosis	other-disease
(	O
desmoid	other-disease
tumors	other-disease
)	O
of	O
the	O
retroperitoneum	O
.	O

Besides	O
,	O
safe	O
blood	O
and	O
blood	O
components	O
service	O
,	O
the	O
trust	O
also	O
runs	O
a	O
thalassaemia	other-disease
centre	O
.	O

Adrenocortical	other-disease
carcinoma	other-disease
has	O
often	O
invaded	O
nearby	O
tissues	O
or	O
metastasized	O
to	O
distant	O
organs	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
and	O
the	O
overall	O
5-year	O
survival	O
rate	O
is	O
about	O
50	O
%	O
.	O

There	O
is	O
increasing	O
evidence	O
in	O
support	O
of	O
genetics	O
being	O
a	O
key	O
factor	O
in	O
the	O
development	O
of	O
OIH	other-disease
through	O
its	O
influence	O
on	O
both	O
pain	O
sensitivity	O
and	O
analgesic	O
control	O
.	O

Social-emotional	other-disease
agnosia	other-disease
often	O
occurs	O
in	O
individuals	O
with	O
schizophrenia	other-disease
and	O
autism	other-disease
.	O

Urinary	other-disease
incontinence	other-disease
and	O
gait	other-disease
apraxia	other-disease
are	O
also	O
not	O
uncommon	O
findings	O
.	O

Adult	O
patients	O
present	O
with	O
clinical	O
history	O
of	O
resistant	O
hypertension	other-disease
despite	O
typical	O
medical	O
therapy	O
and	O
lifestyle	O
changes	O
.	O

These	O
results	O
suggests	O
that	O
loss	O
of	O
function	O
mutations	O
or	O
decreased	O
expression	O
of	O
MIAT	O
is	O
involved	O
in	O
driving	O
aberrant	O
cortical	O
splicing	O
patterns	O
observed	O
in	O
SZ	other-disease
post-mortem	O
brains	O
.	O

About	O
30	O
percent	O
of	O
men	O
with	O
Peyronie	other-disease
's	other-disease
disease	other-disease
develop	O
fibrosis	O
in	O
other	O
elastic	O
tissues	O
of	O
the	O
body	O
,	O
such	O
as	O
on	O
the	O
hand	O
or	O
foot	O
,	O
including	O
Dupuytren	other-disease
's	other-disease
contracture	other-disease
of	O
the	O
hand	O
.	O

This	O
gene	O
,	O
known	O
as	O
ABCA1	O
,	O
has	O
major	O
implications	O
for	O
atherosclerosis	other-disease
and	O
diabetes	other-disease
.	O

Antibodies	O
levels	O
correlate	O
with	O
more	O
severe	O
Guillain–Barré	other-disease
syndrome	other-disease
.	O

Perhaps	O
from	O
traders	O
,	O
the	O
cholera	other-disease
epidemic	O
reached	O
the	O
Plains	O
Indians	O
in	O
1849	O
,	O
resulting	O
in	O
severe	O
loss	O
of	O
life	O
during	O
the	O
summer	O
of	O
that	O
year	O
.	O

HACE	other-disease
can	O
be	O
prevented	O
by	O
ascending	O
to	O
heights	O
slowly	O
to	O
allow	O
the	O
body	O
more	O
time	O
to	O
acclimatize	O
.	O

The	O
procedures	O
to	O
prevent	O
and	O
treat	O
this	O
disease	O
are	O
the	O
main	O
costs	O
involved	O
with	O
Cattle	other-disease
Tick	other-disease
.	O

In	O
the	O
early	O
stages	O
,	O
the	other-disease
gouty	other-disease
arthritis	other-disease
usually	O
occurs	O
in	O
one	O
joint	O
,	O
but	O
with	O
time	O
,	O
it	O
can	O
occur	O
in	O
many	O
joints	O
and	O
be	O
quite	O
crippling	O
.	O

She	O
also	O
helped	O
care	O
for	O
her	O
youngest	O
sister	O
,	O
Stella	O
,	O
who	O
was	O
afflicted	O
by	O
,	O
and	O
died	O
from	O
,	O
polio	other-disease
.	O

Along	O
with	O
Ray	O
Illingworth	O
,	O
Geoff	O
Boycott	O
and	O
John	O
Edrich	O
,	O
John	O
Snow	O
declined	O
to	O
tour	O
India	O
in	O
1972–73	O
,	O
wanting	O
to	O
rest	O
his	O
back	O
for	O
the	O
summer	O
and	O
concerned	O
about	O
the	O
dysentery	other-disease
he	O
had	O
caught	O
in	O
Pakistan	O
in	O
1968–69	O
.	O

It	O
is	O
more	O
severe	O
than	O
the	O
related	O
(	O
and	O
common	O
)	O
disorder	O
known	O
as	O
benign	O
fasciculation	O
syndrome	O
;	O
it	O
causes	O
fasciculations	O
,	O
cramps	O
,	O
pain	O
,	O
fatigue	O
,	O
and	O
muscle	O
stiffness	O
similar	O
to	O
those	O
seen	O
in	O
neuromyotonia	other-disease
(	O
another	O
related	O
condition	O
)	O
.	O

At	O
the	O
end	O
of	O
2003	O
,	O
Drosten	O
,	O
together	O
with	O
Stephan	O
Günther	O
,	O
was	O
awarded	O
a	O
prize	O
by	O
the	O
``	O
Werner	O
Otto	O
Foundation	O
for	O
the	O
Promotion	O
of	O
Medical	O
Research	O
``	O
for	O
the	O
identification	O
of	O
the	O
SARS	other-disease
coronavirus	O
and	O
the	O
establishment	O
of	O
a	O
rapid	O
diagnostic	O
test	O
system	O
.	O

David	O
M.	O
Holtzman	O
is	O
an	O
American	O
neurologist	O
and	O
neuroscientist	O
known	O
for	O
his	O
work	O
exploring	O
the	O
biological	O
mechanisms	O
underlying	O
neurodegeneration	O
,	O
with	O
a	O
focus	O
on	O
Alzheimer	other-disease
's	other-disease
Disease	other-disease
.	O

Type	other-disease
I	other-disease
antithrombin	other-disease
deficiency	other-disease
is	O
characterized	O
by	O
a	O
decrease	O
in	O
both	O
antithrombin	O
activity	O
and	O
antithrombin	O
concentration	O
in	O
the	O
blood	O
of	O
affected	O
individuals	O
.	O

Thickening	O
agents	O
can	O
also	O
be	O
used	O
when	O
a	O
medical	O
condition	O
such	O
as	O
dysphagia	other-disease
causes	O
difficulty	O
in	O
swallowing	O
.	O

It	O
has	O
been	O
stated	O
that	O
cats	O
with	O
FPLV	other-disease
may	O
be	O
at	O
risk	O
for	O
endocarditis	other-disease
or	O
cardiomyopathy	other-disease
(	O
since	O
CPV-2	other-disease
is	O
a	O
well-known	O
cause	O
of	O
viral	other-disease
myocarditis	other-disease
in	O
young	O
puppies	O
)	O
,	O
but	O
a	O
2017	O
retrospective	O
study	O
concluded	O
that	O
``	O
Feline	other-disease
Panleukopenia	other-disease
Virus	other-disease
Is	O
Not	O
Associated	O
With	O
Myocarditis	other-disease
or	O
Endomyocardial	other-disease
Restrictive	other-disease
Cardiomyopathy	other-disease
in	O
Cats	O
''	O
.	O

Alter	O
demonstrated	O
through	O
the	O
serologic	O
exclusion	O
of	O
Hepatitis	other-disease
A	other-disease
and	O
Hepatitis	other-disease
B	other-disease
that	O
a	O
third	O
,	O
previously	O
unrecognised	O
form	O
of	O
viral	O
hepatitis	O
existed	O
,	O
originally	O
named	O
non-A	other-disease
,	other-disease
non-B	other-disease
hepatitis	other-disease
(	O
NANBH	other-disease
)	O
.	O

Melatonin	O
has	O
been	O
shown	O
to	O
mitigate	O
the	O
growth	O
of	O
tumors	other-disease
in	O
rats	O
.	O

Borna	other-disease
disease	O
,	O
also	O
known	O
as	O
sad	O
horse	other-disease
disease	other-disease
,	O
is	O
an	O
infectious	O
neurological	O
syndrome	O
of	O
warm-blooded	O
animals	O
,	O
caused	O
by	O
Borna	other-disease
disease	O
viruses	other-disease
1	other-disease
and	other-disease
2	other-disease
(	O
BoDV-1/2	other-disease
)	O
,	O
both	O
of	O
which	O
are	O
members	O
of	O
the	O
species	O
``	O
Mammalian	other-disease
1	other-disease
orthobornavirus	other-disease
``	O
.	O

2	O
)	O
Heart	other-disease
failure	other-disease
with	other-disease
preserved	other-disease
ejection	other-disease
fraction	other-disease
(	O
HFpEF	other-disease
)	O
:	O
Synonyms	O
no	O
longer	O
recommended	O
include	O
``	O
diastolic	other-disease
heart	other-disease
failure	other-disease
``	O
and	O
``	O
heart	other-disease
failure	other-disease
with	O
normal	O
ejection	O
fraction	O
.	O
''	O

In	O
the	O
US	O
,	O
venetoclax	O
is	O
indicated	O
for	O
adults	O
with	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	other-disease
)	O
or	O
small	O
lymphocytic	O
lymphoma	O
(	O
SLL	other-disease
)	O
.	O

Women	O
with	O
fibroids	other-disease
do	O
not	O
always	O
have	O
symptoms	O
,	O
but	O
some	O
experience	O
vaginal	O
bleeding	O
between	O
periods	O
,	O
pain	O
during	O
sex	O
,	O
and	O
lower	O
back	O
pain	O
.	O

In	O
2013	O
,	O
a	O
study	O
revealed	O
that	O
1	O
in	O
2,000	O
people	O
in	O
the	O
United	O
Kingdom	O
might	O
harbour	O
the	O
infectious	O
prion	O
protein	O
that	O
causes	O
vCJD	other-disease
.	O

Maternal	O
obesity	O
refers	O
to	O
obesity	other-disease
(	O
often	O
including	O
being	O
overweight	O
)	O
of	O
a	O
woman	O
during	O
pregnancy	O
.	O

About	O
one	O
in	O
eight	O
Americans	O
(	O
as	O
of	O
2007	O
)	O
have	O
chronic	other-disease
kidney	other-disease
disease	other-disease
,	O
a	O
rate	O
that	O
is	O
increasing	O
over	O
time	O
.	O

It	O
is	O
a	O
RASopathy	other-disease
.	O

However	O
,	O
the	O
significance	O
of	O
GPC3	O
as	O
a	O
diagnostic	O
tool	O
for	O
human	O
tumors	O
other	O
than	O
HCC	other-disease
is	O
unclear	O
.	O

Since	O
many	O
,	O
if	O
not	O
most	O
,	O
anal	other-disease
cancers	other-disease
derive	O
from	O
HPV	O
infections	O
,	O
and	O
since	O
the	O
HPV	O
vaccine	O
before	O
exposure	O
to	O
HPV	O
prevents	O
infection	O
by	O
some	O
strains	O
of	O
the	O
virus	O
and	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
incidence	O
of	O
potentially	O
precancerous	O
lesions	O
,	O
scientists	O
surmise	O
that	O
HPV	O
vaccination	O
may	O
reduce	O
the	O
incidence	O
of	O
anal	other-disease
cancer	other-disease
.	O

After	O
Vito	O
dies	O
in	O
1955	O
from	O
a	O
heart	other-disease
attack	other-disease
,	O
Michael	O
has	O
the	O
other	O
New	O
York	O
Dons	O
murdered	O
,	O
including	O
Barzini	O
,	O
who	O
is	O
shot	O
twice	O
in	O
the	O
back	O
on	O
the	O
steps	O
of	O
a	O
courthouse	O
in	O
broad	O
daylight	O
.	O

This	O
virus	O
is	O
quite	O
distinct	O
from	O
the	O
other	O
known	O
Hepatitis	other-disease
E	other-disease
viruses	other-disease
.	O

This	O
means	O
that	O
the	O
associated	O
tachycardia	O
may	O
be	O
subclinical	O
and	O
only	O
diagnosed	O
at	O
a	O
late	O
stage	O
,	O
after	O
significant	O
damage	O
to	O
the	O
heart	O
has	O
been	O
caused	O
from	O
prolonged	O
and	O
recurrent	O
episodes	O
of	O
AVRT	other-disease
.	O

Studies	O
show	O
that	O
a	O
woman	O
who	O
has	O
had	O
one	O
child	O
with	O
a	O
neural	O
tube	O
defect	O
such	O
as	O
anencephaly	other-disease
has	O
about	O
a	O
3	O
%	O
risk	O
of	O
having	O
another	O
child	O
with	O
a	O
neural	O
tube	O
defect	O
,	O
as	O
opposed	O
to	O
the	O
background	O
rate	O
of	O
0.1	O
%	O
occurrence	O
in	O
the	O
population	O
at	O
large	O
.	O

In	O
polycythaemia	other-disease
vera	other-disease
,	O
the	O
most	O
common	O
side	O
effects	O
include	O
thrombocytopenia	other-disease
(	O
low	O
blood	O
platelet	O
counts	O
)	O
,	O
anaemia	other-disease
(	O
low	O
red	O
blood	O
cell	O
counts	O
)	O
,	O
bleeding	O
,	O
bruising	O
,	O
hypercholesterolaemia	other-disease
(	O
high	O
blood	O
cholesterol	O
levels	O
)	O
,	O
hypertriglyceridemia	other-disease
(	O
high	O
blood	O
fat	O
levels	O
)	O
,	O
dizziness	O
,	O
raised	O
liver	O
enzyme	O
levels	O
and	O
high	O
blood	O
pressure	O
.	O

McCarter	O
died	O
in	O
Tampa	O
,	O
Florida	O
on	O
December	O
22	O
,	O
2015	O
,	O
at	O
the	O
age	O
of	O
52	O
from	O
the	O
genetic	O
liver	O
disorder	O
alpha	O
1-antitrypsin	O
deficiency	O
(	O
AAT	other-disease
)	O
.	O

Diabetes	other-disease
mellitus	other-disease
is	O
the	O
most	O
common	O
risk	O
factor	O
involved	O
.	O

The	O
economic	O
collapse	O
following	O
the	O
2020	O
COVID-19	other-disease
pandemic	O
is	O
projected	O
to	O
cause	O
$	O
8	O
billion	O
to	O
$	O
12	O
billion	O
in	O
lost	O
tax	O
revenue	O
for	O
Sound	O
Transit	O
through	O
the	O
end	O
of	O
the	O
ST3	O
program	O
in	O
2041	O
.	O

Another	O
less	O
commonly	O
known	O
aphasia	other-disease
is	O
global	other-disease
aphasia	other-disease
,	O
which	O
generally	O
manifests	O
itself	O
after	O
a	O
stroke	other-disease
affecting	O
an	O
extensive	O
portion	O
of	O
the	O
brain	O
occurs	O
,	O
including	O
infarction	O
of	O
both	O
divisions	O
of	O
the	O
middle	O
cerebral	O
artery	O
and	O
generally	O
both	O
Broca	O
's	O
area	O
and	O
Wernicke	O
's	O
area	O
.	O

Under	O
the	O
directorships	O
of	O
Mullan	O
and	O
Crawford	O
the	O
Roskamp	O
Institute	O
focuses	O
on	O
discovering	O
new	O
treatments	O
for	O
Alzheimer	other-disease
's	O
disease	O
,	O
traumatic	other-disease
brain	other-disease
injury	other-disease
,	O
multiple	other-disease
sclerosis	other-disease
,	O
Gulf	O
War	O
illness	O

Kallmann	other-disease
syndrome	other-disease
can	O
also	O
be	O
shown	O
through	O
MRI	O
imaging	O
with	O
irregular	O
morphology	O
or	O
aplasia	O
of	O
the	O
olfactory	O
bulb	O
and	O
olfactory	O
sulci	O
.	O

Influenza	other-disease
B	other-disease
and	other-disease
C	other-disease
principally	O
infect	O
humans	O
,	O
minimizing	O
the	O
chance	O
that	O
a	O
reassortment	O
will	O
change	O
its	O
phenotype	O
drastically	O
.	O

Aged	O
between	O
19	O
and	O
23	O
,	O
one	O
person	O
,	O
Lewis	O
,	O
has	O
Williams	other-disease
syndrome	other-disease
while	O
the	O
others	O
have	O
Down	other-disease
syndrome	other-disease
.	O

When	O
the	O
bacteria	O
are	O
in	O
vivo	O
,	O
they	O
induce	O
flaccid	other-disease
paralysis	other-disease
.	O

For	O
those	O
with	O
diabetes	other-disease
,	O
using	O
purified	O
insulins	O
may	O
also	O
help	O
.	O

These	O
cases	O
should	O
have	O
no	O
symptoms	O
or	O
findings	O
of	O
end	O
organ	O
dysfunction	O
attributed	O
to	O
Waldenström	other-disease
's	other-disease
macroglobulinemia	other-disease
such	O
as	O
anemia	other-disease
,	O
decreases	O
in	O
any	O
white	O
blood	O
cell	O
count	O
,	O
cold	other-disease
agglutinin	other-disease
disease	other-disease
,	O
hyperviscosity	other-disease
of	other-disease
blood	other-disease
,	O
lymphadenopathy	other-disease
,	O
hepatomegaly	other-disease
,	O
splenomegaly	other-disease
,	O
peripheral	other-disease
neuropathy	other-disease
,	O
cryoglobulinemia	other-disease
,	O
or	O
constitutional	O
symptoms	O
.	O

In	O
2009	O
,	O
he	O
had	O
major	O
groin	O
surgery	O
for	O
his	O
osteitis	other-disease
pubis	other-disease
.	O

So	O
,	O
MDM2	O
blockade	O
had	O
mostly	O
anti-inflammatory	O
and	O
anti-mitotic	O
effects	O
that	O
can	O
be	O
of	O
additive	O
therapeutic	O
efficacy	O
in	O
inflammatory	O
and	O
hyperproliferative	other-disease
disorders	other-disease
such	O
as	O
certain	O
cancers	other-disease
or	O
lymphoproliferative	other-disease
autoimmunity	other-disease
,	O
such	O
as	O
systemic	other-disease
lupus	other-disease
erythematosus	other-disease
or	O
crescentic	other-disease
glomerulonephritis	other-disease
.	O

Fungi	O
responsible	O
for	O
fungal	O
sinusitis	O
are	O
``	O
Aspergillus	other-disease
fumigatus	other-disease
``	O
(	O
90	O
%	O
)	O
,	O
``	O
Aspergillus	other-disease
flavus	other-disease
``	O
,	O
and	O
``	O
Aspergillus	other-disease
niger	other-disease
``	O
.	O

During	O
the	O
2020	O
Coronavirus	other-disease
Pandemic	other-disease
,	O
the	O
BBC	O
announced	O
a	O
decision	O
not	O
to	O
feature	O
``	O
Land	O
of	O
Hope	O
and	O
Glory	O
``	O
as	O
well	O
as	O
Rule	O
Britannia	O
in	O
the	O
Last	O
Night	O
of	O
the	O
Proms	O
running	O
order	O
.	O

Splenomegaly	other-disease
may	O
also	O
come	O
from	O
bacterial	O
infections	O
,	O
such	O
as	O
syphilis	other-disease
or	O
an	O
infection	O
of	O
the	O
heart	O
's	O
inner	O
lining	O
(	O
endocarditis	other-disease
)	O
.	O

Akiyama	O
died	O
of	O
peritonitis	other-disease
in	O
1918	O
at	O
the	O
young	O
age	O
of	O
49	O
(	O
In	O
the	O
East	O
Asian	O
age	O
reckoning	O
,	O
it	O
is	O
sometimes	O
described	O
as	O
being	O
51	O
years	O
old	O
)	O
,	O
His	O
grave	O
is	O
at	O
Aoyama	O
Cemetery	O
in	O
Tokyo	O
.	O

It	O
has	O
a	O
similar	O
pathology	O
to	O
Sandhoff	other-disease
disease	O
and	O
Tay–Sachs	other-disease
disease	O
.	O

The	O
cytogenetic	O
location	O
of	O
the	O
gene	O
in	O
question	O
is	O
chromosome	O
3	O
,	O
specifically	O
3q11.1	O
Protein	O
S	O
deficiency	O
can	O
also	O
be	O
``	O
acquired	O
''	O
due	O
to	O
vitamin	O
K	O
deficiency	O
,	O
treatment	O
with	O
warfarin	other-disease
,	O
liver	O
disease	O
,	O
and	O
acute	other-disease
thrombosis	other-disease
(	O
antiphospholipid	O
antibodies	O
may	O
also	O
be	O
a	O
cause	O
as	O
well	O
)	O

Daubert	O
and	O
Schuller	O
submitted	O
expert	O
evidence	O
of	O
their	O
own	O
that	O
suggested	O
that	O
Bendectin	other-disease
could	O
cause	O
birth	O
defects	O
.	O

Dengue	other-disease
fever	other-disease
has	O
become	O
endemic	O
to	O
the	O
republic	O
,	O
cases	O
of	O
malaria	other-disease
,	O
and	O
Zika	other-disease
virus	other-disease
.	O

It	O
was	O
likely	O
that	O
he	O
died	O
for	O
other	O
reasons	O
,	O
not	O
sleep	O
deprivation	O
,	O
as	O
his	O
insomnia	other-disease
did	O
not	O
seem	O
to	O
have	O
any	O
effect	O
on	O
his	O
health	O
.	O

Drug	O
and	O
alcohol	O
use	O
during	O
pregnancy	O
can	O
lead	O
to	O
many	O
health	O
problems	O
in	O
the	O
fetus	O
and	O
baby	O
,	O
Neonatal	other-disease
Abstinence	other-disease
Syndrome	other-disease
(	O
NAS	other-disease
)	O
.	O

Many	O
scientists	O
also	O
categorize	O
Parkinson	other-disease
disease	O
and	O
familial	other-disease
dysautonomia	other-disease
as	O
``	O
primary	O
''	O
.	O

PKU	other-disease
-affected	O
women	O
themselves	O
are	O
not	O
at	O
risk	O
of	O
additional	O
complications	O
during	O
pregnancy	O
.	O

It	O
can	O
also	O
cause	O
a	O
type	O
of	O
septicaemia	other-disease
called	O
pyaemia	other-disease
.	O

In	O
recognition	O
of	O
World	O
AIDS	other-disease
Day	O
on	O
December	O
1	O
,	O
2009	O
,	O
AIDS	other-disease
.gov	O
again	O
hosted	O
the	O
Facing	O
AIDS	other-disease
initiative	O
,	O
among	O
other	O
activities	O
.	O

Common	O
conditions	O
that	O
reduce	O
serum	O
albumin	O
in	O
the	O
clinical	O
setting	O
are	O
hemorrhage	other-disease
,	O
nephrotic	other-disease
syndrome	other-disease
,	O
intestinal	other-disease
obstruction	other-disease
and	O
liver	other-disease
cirrhosis	other-disease
.	O

The	O
most	O
common	O
type	O
of	O
pituitary	other-disease
tumour	other-disease
is	O
a	O
prolactinoma	O
which	O
hypersecretes	O
prolactin	O
.	O

LET	O
resolves	O
with	O
normal	O
skin	O
,	O
no	O
residual	O
scarring	O
,	O
no	O
hyperpigmentation	other-disease
or	O
hypopigmentation	other-disease
.	O

The	O
disorder	O
is	O
confined	O
to	O
the	O
penis	O
,	O
although	O
a	O
substantial	O
number	O
of	O
men	O
with	O
Peyronie	other-disease
's	other-disease
exhibit	O
concurrent	O
connective	O
tissue	O
disorders	O
in	O
the	O
hand	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
,	O
in	O
the	O
feet	O
.	O

His	O
interest	O
in	O
cholera	other-disease
epidemics	other-disease
started	O
in	O
1994	O
while	O
working	O
as	O
a	O
volunteer	O
pediatrician	O
in	O
Goma	O
,	O
Zaire	O
during	O
an	O
extensive	O
cholera	other-disease
outbreak	O
following	O
the	O
Rwandan	O
genocide	O
.	O

virus	O
infection	O
may	O
be	O
either	O
acute	O
(	O
self-limiting	other-disease
)	O
or	O
chronic	O
(	O
long-standing	O
)	O
.	O

It	O
is	O
a	O
rare	O
hereditary	O
disorder	O
that	O
generally	O
comes	O
to	O
light	O
when	O
a	O
patient	O
suffers	O
recurrent	other-disease
venous	other-disease
thrombosis	other-disease
and	O
pulmonary	other-disease
embolism	other-disease
,	O
and	O
repetitive	O
intrauterine	other-disease
fetal	other-disease
death	other-disease
(	O
IUFD	other-disease
)	O
.	O

During	O
the	O
conference	O
's	O
closing	O
ceremonies	O
,	O
United	O
Nations	O
Special	O
Envoy	O
for	O
HIV/AIDS	O
in	O
Africa	O
Stephen	O
Lewis	O
pointed	O
out	O
the	O
failure	O
of	O
South	O
Africa	O
's	O
response	O
to	O
HIV	other-disease
/	O
AIDS	other-disease
,	O
calling	O
their	O
actions	O
more	O
``	O
[	O
more	O
]	O
worthy	O
of	O
a	O
lunatic	O
fringe	O
than	O
of	O
a	O
concerned	O
and	O
compassionate	O
state	O
.	O
''	O

A	O
2004	O
WHO	O
resolution	O
``	O
called	O
for	O
increasing	O
surveillance	O
and	O
control	O
,	O
and	O
for	O
intensified	O
research	O
to	O
develop	O
tools	O
to	O
diagnose	O
,	O
treat	O
and	O
prevent	O
''	O
Buruli	other-disease
ulcer	other-disease
.	O

Genetic	O
counseling	O
is	O
usually	O
offered	O
to	O
women	O
at	O
a	O
higher	O
risk	O
of	O
having	O
a	O
child	O
with	O
a	O
neural	O
tube	O
defect	O
to	O
discuss	O
available	O
testing.It	O
is	O
known	O
that	O
people	O
taking	O
certain	O
anticonvulsants	O
and	O
people	O
with	O
insulin-dependent	O
diabetes	O
have	O
a	O
higher	O
risk	O
of	O
having	O
a	O
child	O
with	O
a	O
neural	other-disease
tube	other-disease
defect	other-disease
.	O

Acquired	other-disease
and	other-disease
secondary	other-disease
strabismus	other-disease
develop	O
later	O
.	O

Mann	O
thought	O
Nakajima	O
was	O
not	O
aggressive	O
enough	O
in	O
his	O
approach	O
against	O
AIDS	other-disease
.	O

Lingual	other-disease
thyroid	other-disease
may	O
be	O
asymptomatic	O
,	O
or	O
give	O
symptoms	O
such	O
as	O
dysphagia	O
(	O
difficulty	O
swallowing	O
)	O
,	O
dysphonia	O
(	O
difficulty	O
talking	O
)	O
and	O
dyspnea	O
(	O
difficulty	O
breathing	O
)	O
.	O

Rarer	O
causes	O
include	O
hereditary	O
hemorrhagic	O
telangiectasia	O
(	O
HHT	other-disease
or	O
Rendu-Osler-Weber	other-disease
syndrome	O
)	O
,	O
Goodpasture	other-disease
's	O
syndrome	O
,	O
and	O
granulomatosis	O
with	O
polyangiitis	O
.	O

The	O
symptoms	O
of	O
early	other-disease
menopause	other-disease
may	O
be	O
more	O
severe	O
.	O

Hyperglycemia	other-disease
is	O
also	O
a	O
common	O
side	O
effect	O
.	O

Erectile	other-disease
dysfunction	other-disease
occurs	O
for	O
a	O
variety	O
of	O
reasons	O
.	O

Psychiatrist	O
Edward	O
J.	O
Kempf	O
coined	O
the	O
term	O
``	O
Homosexual	other-disease
panic	other-disease
``	O
in	O
1920	O
and	O
identified	O
it	O
as	O
a	O
condition	O
of	O
``	O
panic	O
due	O
to	O
the	O
pressure	O
of	O
uncontrollable	O
perverse	O
sexual	O
cravings	O
''	O
.	O

Other	O
studies	O
have	O
also	O
suggested	O
that	O
plantar	other-disease
fasciitis	other-disease
is	O
not	O
due	O
to	O
the	O
inflamed	O
plantar	O
fascia	O
but	O
maybe	O
a	O
tendon	O
injury	O
involving	O
the	O
flexor	O
digitorum	O
brevis	O
muscle	O
located	O
immediately	O
deep	O
to	O
the	O
plantar	O
fascia	O
.	O

Panhypopituitarism	O
and	O
hypothyroidism	other-disease
have	O
each	O
been	O
diagnosed	O
in	O
a	O
handful	O
of	O
individuals	O
.	O

In	O
1998	O
,	O
a	O
case	O
of	O
``	O
S.	O
equinus	O
``	O
peritonitis	other-disease
in	O
a	O
patient	O
on	O
continuous	other-disease
ambulatory	other-disease
peritoneal	other-disease
dialysis	other-disease
(	O
CAPD	other-disease
)	O
was	O
reported	O
.	O

The	O
symptoms	O
of	O
dementia	O
with	O
Lewy	other-disease
bodies	other-disease
(	O
DLB	other-disease
)	O
are	O
more	O
frequent	O
,	O
more	O
severe	O
,	O
and	O
earlier	O
presenting	O
than	O
in	O
the	O
other	O
dementia	O
subtypes	O
.	O

Darlix	O
and	O
Lathe	O
propose	O
that	O
retroelements	O
constitute	O
the	O
replicative	O
component	O
of	O
the	O
transmissible	other-disease
spongiform	other-disease
encephalopathies	other-disease
.	O

It	O
may	O
be	O
also	O
useful	O
in	O
adult	O
PTSD	other-disease
patients	O
who	O
do	O
not	O
respond	O
to	O
SSRIs	other-disease
.	O

Saint	O
Adeodatus	O
participated	O
as	O
bishop	O
of	O
this	O
episcopal	O
see	O
,	O
in	O
a	O
synod	O
at	O
Rome	O
called	O
by	O
Pope	O
Symmachus	O
in	O
499	O
,	O
shortly	O
before	O
the	O
seat	O
of	O
the	O
bishopric	O
was	O
moved	O
,	O
because	O
of	O
malaria	other-disease
,	O
from	O
Caere	O
Vetus	O
(	O
today	O
's	O
Cerveteri	O
)	O
to	O
the	O
new	O
settlement	O
of	O
Caere	O
Nova	O
(	O
today	O
's	O
Ceri	O
)	O
.	O

With	O
considerable	O
speech	O
therapy	O
rehabilitation	O
,	O
global	other-disease
aphasia	other-disease
may	O
progress	O
into	O
expressive	other-disease
aphasia	other-disease
or	O
receptive	other-disease
aphasia	other-disease
.	O

It	O
causes	O
profound	O
amnesia	other-disease
but	O
allows	O
spontaneous	O
respiration	O
,	O
cardiopulmonary	O
stability	O
,	O
and	O
airway	O
reflexes	O
are	O
still	O
intact	O
.	O

Radiation	O
exposure	O
increases	O
the	O
risk	O
of	O
primary	other-disease
hyperparathyroidism	other-disease
.	O

feline	other-disease
urinary	other-disease
tract	other-disease
infections	other-disease
or	O
urolithiasis	other-disease
)	O
are	O
ruled	O
out	O
.	O

Recombinant	O
erythropoietin	O
(	O
EPO	O
)	O
is	O
very	O
effective	O
in	O
treating	O
the	O
diminished	O
red	O
blood	O
cell	O
production	O
that	O
accompanies	O
end-stage	other-disease
kidney	other-disease
disease	other-disease
.	O

His	O
death	O
certificate	O
gave	O
the	O
cause	O
of	O
death	O
as	O
tuberculosis	other-disease
,	O
and	O
his	O
physician	O
,	O
Cruveilhier	O
,	O
was	O
then	O
the	O
leading	O
French	O
authority	O
on	O
this	O
disease	O
.	O

In	O
1994	O
,	O
Scruggs	O
teamed	O
with	O
Earl	O
Scruggs	O
and	O
Doc	O
Watson	O
to	O
contribute	O
the	O
song	O
``	O
Keep	O
on	O
the	O
Sunny	O
Side	O
``	O
to	O
the	O
AIDS	other-disease
benefit	O
album	O
Red	O
Hot	O
+	O
Country	O
produced	O
by	O
the	O
Red	O
Hot	O
Organization	O
.	O

Acute	other-disease
ischemic	other-disease
stroke	other-disease
is	O
a	O
neurologic	O
emergency	O
that	O
may	O
be	O
reversible	O
if	O
treated	O
rapidly	O
.	O

Washkansky	O
,	O
however	O
,	O
died	O
18	O
days	O
later	O
from	O
pneumonia	other-disease
.	O

Using	O
his	O
theory	O
and	O
reading	O
John	O
Snow	O
's	O
essay	O
about	O
cholera	other-disease
in	O
London	O
(	O
1849	O
)	O
,	O
Budd	O
took	O
measures	O
to	O
protect	O
the	O
Bristol	O
's	O
water	O
supply	O
.	O

This	O
concept	O
was	O
exemplified	O
in	O
2007	O
when	O
a	O
California	O
woman	O
died	O
of	O
water	other-disease
intoxication	other-disease
in	O
a	O
contest	O
sanctioned	O
by	O
a	O
radio	O
station	O
.	O

Ecury	O
died	O
on	O
2	O
March	O
2012	O
in	O
Willemstad	O
,	O
after	O
a	O
five	O
year	O
struggle	O
with	O
Alzheimer	other-disease
’	O
s	O
disease	O
.	O

Direct	O
intervention	O
for	O
psychological	O
treatment	O
of	O
childhood	other-disease
obesity	other-disease
has	O
become	O
more	O
prevalent	O
in	O
recent	O
years	O
.	O

However	O
,	O
the	O
effect	O
of	O
acid-base	O
balance	O
can	O
be	O
variable	O
as	O
patients	O
with	O
large	other-disease
GI	other-disease
losses	other-disease
can	O
become	O
alkalotic	other-disease
.	O

He	O
seek	O
to	O
improve	O
hypertension	other-disease
control	O
,	O
unhealthy	O
diets	O
and	O
physical	O
inactivity	O
on	O
a	O
national	O
and	O
global	O
scale	O
.	O

In	O
1986	O
,	O
the	O
hospital	O
was	O
at	O
the	O
center	O
of	O
a	O
criminal	O
case	O
after	O
a	O
GBI	other-disease
investigation	O
following	O
an	O
unusually	O
high	O
percentage	O
of	O
cardiac	O
arrests	O
.	O

Catatonia	other-disease
can	O
be	O
stuporous	O
or	O
excited	O
.	O

Dwarfism	other-disease
was	O
not	O
seen	O
as	O
a	O
defect	O
in	O
ancient	O
Egypt	O
,	O
unlike	O
in	O
many	O
other	O
cultures	O
.	O

Professor	O
Akiskal	O
rose	O
to	O
prominence	O
with	O
his	O
integrative	O
theory	O
of	O
depression	other-disease
.	O

Lupus	other-disease
erythematosus	other-disease
tumidus	other-disease
(	O
LET	other-disease
)	O
was	O
reported	O
by	O
Henri	O
Gougerot	O
and	O
Burnier	O
R	O
.	O
in	O
1930	O
.	O

Before	O
1970	O
,	O
survival	O
rates	O
from	O
testicular	other-disease
cancer	other-disease
were	O
low	O
.	O

In	O
addition	O
to	O
sometimes	O
being	O
a	O
symptom	O
of	O
dysautonomia	other-disease
,	O
anxiety	O
can	O
sometimes	O
physically	O
manifest	O
symptoms	O
resembling	O
autonomic	O
dysfunction	other-disease
.	O

the	O
typical	O
COPD	other-disease
patient	O
averages	O
two	O
to	O
three	O
AECB	other-disease
episodes	O
per	O
year	O
.	O

These	O
types	O
of	O
lipodystrophies	other-disease
are	O
harmless	O
and	O
can	O
be	O
avoided	O
by	O
changing	O
(	O
rotating	O
)	O
the	O
locations	O
of	O
injections	O
.	O

Malaria	other-disease
due	O
to	O
``	O
Plasmodium	O
falciparum	O
``	O
is	O
a	O
major	O
selective	O
factor	O
in	O
human	O
evolution	O
.	O

It	O
has	O
been	O
observed	O
that	O
patients	O
with	O
MERRF	other-disease
syndrome	O
will	O
primarily	O
display	O
myoclonus	O
as	O
a	O
first	O
symptom	O
.	O

Budd	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
credited	O
with	O
decreasing	O
the	O
incidence	O
of	O
deaths	O
in	O
Bristol	O
from	O
cholera	other-disease
,	O
from	O
2000	O
(	O
out	O
of	O
a	O
population	O
of	O
140,000	O
)	O
in	O
1849	O
to	O
29	O
in	O
1866	O
.	O

Morquio	other-disease
syndrome	other-disease
,	O
also	O
known	O
as	O
Mucopolysaccharidosis	other-disease
Type	other-disease
IV	other-disease
(	O
MPS	other-disease
IV	other-disease
)	O
,	O
is	O
a	O
rare	O
metabolic	O
disorder	O
in	O
which	O
the	O
body	O
can	O
not	O
process	O
certain	O
types	O
of	O
sugar	O
molecules	O
called	O
glycosaminoglycans	O
(	O
AKA	O
GAGs	O
,	O
or	O
mucopolysaccharides	O
)	O
.	O

Aphasic	other-disease
people	O
are	O
still	O
able	O
to	O
comprehend	O
speech	O
as	O
the	O
lesion	O
does	O
not	O
disrupt	O
the	O
ventral	O
stream	O
pathway	O
.	O

The	O
link	O
of	O
SKI	O
with	O
human	O
melanoma	other-disease
has	O
been	O
the	O
most	O
studied	O
area	O
of	O
the	O
protein	O
’	O
s	O
link	O
to	O
cancer	O
.	O

The	O
only	O
sign	O
of	O
BFNE	other-disease
are	O
seizures	O
,	O
generally	O
tonic-clonic	O
,	O
which	O
occur	O
within	O
the	O
first	O
week	O
of	O
life	O
.	O

ARS	other-disease
differs	O
from	O
chronic	other-disease
radiation	other-disease
syndrome	other-disease
,	O
which	O
occurs	O
following	O
prolonged	O
exposures	O
to	O
relatively	O
low	O
doses	O
of	O
radiation	O
.	O

At	O
this	O
time	O
a	O
home	O
for	O
ex-	O
Hansen	other-disease
's	O
disease	O
patients	O
was	O
being	O
built	O
on	O
Palm	O
Island	O
.	O

The	O
mitogenic	O
role	O
of	O
MDM2	O
is	O
also	O
needed	O
for	O
wound	O
healing	O
upon	O
tissue	O
injury	O
,	O
while	O
MDM2	O
inhibition	O
impairs	O
re-epithelialization	O
upon	O
epithelial	other-disease
damage	other-disease
.	O

Roberts	O
died	O
on	O
April	O
26	O
,	O
2014	O
;	O
occlusive	other-disease
coronary	other-disease
artery	other-disease
disease	other-disease
and	O
cardiomegaly	other-disease
contributed	O
to	O
his	O
death	O
.	O

This	O
was	O
the	O
first	O
program	O
in	O
the	O
world	O
to	O
use	O
HIV	other-disease
positive	O
donors	O
for	O
HIV	other-disease
positive	O
recipients	O
.	O

Familial	other-disease
dysalbuminemic	other-disease
hyperthyroxinemia	other-disease
is	O
a	O
type	O
of	O
hyperthyroxinemia	other-disease
associated	O
with	O
mutations	O
in	O
the	O
human	O
serum	O
albumin	O
gene	O
.	O

Schizotypal	other-disease
personality	other-disease
disorder	other-disease
is	O
widely	O
understood	O
to	O
be	O
a	O
``	O
schizophrenia	other-disease
spectrum	other-disease
``	O
disorder	O
.	O

Both	O
occupational	other-disease
asthma	other-disease
and	O
work-exacerbated	other-disease
asthma	other-disease
can	O
be	O
present	O
in	O
an	O
individual	O
.	O

PJRT	other-disease
can	O
cause	O
chronic	O
tachycardia	O
that	O
,	O
untreated	O
,	O
leads	O
to	O
cardiomyopathy	O
.	O

In	O
kidney	other-disease
cancer	other-disease
,	O
this	O
effect	O
could	O
be	O
due	O
to	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
von	O
Hippel–Lindau	O
tumor	O
suppressor	O
gene	O
upregulating	O
glycolytic	O
enzymes	O
,	O
including	O
the	O
M2	O
splice	O
isoform	O
of	O
pyruvate	O
kinase	O
.	O

A	O
study	O
of	O
the	O
relationship	O
of	O
literacy	O
to	O
asthma	other-disease
knowledge	O
revealed	O
that	O
31	O
%	O
of	O
asthma	other-disease
patients	O
with	O
a	O
reading	O
level	O
of	O
a	O
ten-year-old	O
knew	O
they	O
needed	O
to	O
see	O
the	O
doctors	O
,	O
even	O
when	O
they	O
were	O
not	O
having	O
an	O
asthma	other-disease
attack	O
,	O
compared	O
to	O
90	O
%	O
with	O
a	O
high	O
school	O
graduate	O
reading	O
level	O
.	O

It	O
is	O
a	O
supraventricular	O
tachycardia	O
,	O
and	O
a	O
cause	O
of	O
atrioventricular	other-disease
reentrant	other-disease
tachycardia	other-disease
(	O
AVRT	other-disease
)	O
.	O

Despite	O
their	O
local	O
infiltrative	O
and	O
aggressive	O
behavior	O
,	O
mortality	O
is	O
minimal	O
to	O
nonexistent	O
for	O
peripheral	other-disease
tumours	other-disease
.	O

Hepatitis	other-disease
A	other-disease
is	O
usually	O
spread	O
when	O
the	O
virus	O
is	O
taken	O
in	O
through	O
the	O
mouth	O
through	O
coming	O
in	O
contact	O
with	O
objects	O
,	O
food	O
,	O
or	O
drinks	O
that	O
have	O
been	O
contaminated	O
by	O
the	O
feces	O
of	O
an	O
infected	O
person	O
.	O

Social-emotional	other-disease
agnosia	other-disease
,	O
also	O
known	O
as	O
emotional	other-disease
agnosia	other-disease
or	O
expressive	other-disease
agnosia	other-disease
,	O
is	O
the	O
inability	O
to	O
perceive	O
facial	O
expressions	O
,	O
body	O
language	O
,	O
and	O
voice	O
intonation	O
.	O

Lymphoedema	other-disease
may	O
develop	O
in	O
many	O
cases	O
accompanied	O
by	O
acral	O
thickening	O
of	O
the	O
skin	O
folds	O
,	O
hyperkeratosis	other-disease
and	O
papillomatosis	other-disease
.	O

The	O
Treatment	O
Action	O
Campaign	O
(	O
TAC	O
)	O
is	O
a	O
South	O
African	O
HIV	other-disease
/	O
AIDS	other-disease
activist	O
organisation	O
which	O
was	O
co-founded	O
by	O
the	O
HIV	other-disease
-positive	O
activist	O
Zackie	O
Achmat	O
in	O
1998	O
.	O

Gordon	O
A.	O
Alles	O
(	O
November	O
26	O
,	O
1901	O
–	O
January	O
21	O
,	O
1963	O
)	O
,	O
was	O
an	O
American	O
chemist	O
and	O
pharmacologist	O
who	O
did	O
extensive	O
research	O
on	O
the	O
isolation	O
and	O
properties	O
of	O
insulin	O
for	O
the	O
treatment	O
of	O
diabetics	other-disease
.	O

It	O
is	O
found	O
Anik	O
is	O
suffering	O
from	O
Brain	other-disease
Tumour	other-disease
and	O
he	O
is	O
admitted	O
to	O
hospital	O
for	O
treatment	O
under	O
surgeon	O
Dr	O
Ashok	O
Mukherjee	O
.	O

Although	O
Jenner	O
was	O
not	O
the	O
first	O
person	O
to	O
conceive	O
the	O
notion	O
of	O
cowpox	other-disease
protecting	O
against	O
the	O
smallpox	other-disease
virus	O
,	O
his	O
experiment	O
proved	O
the	O
theory	O
.	O

For	O
example	O
,	O
one	O
group	O
found	O
a	O
positive	O
correlation	O
between	O
persistently	O
activated	O
tyrosine-phosphorylated	O
STAT3	O
(	O
pSTAT3	O
)	O
,	O
found	O
in	O
50	O
%	O
of	O
lung	other-disease
adenocarcinomas	other-disease
,	O
and	O
IL-6	O
.	O

After	O
antiviral	O
properties	O
were	O
initially	O
reported	O
in	O
1963	O
,	O
amantadine	O
received	O
approval	O
for	O
prophylaxis	O
against	O
the	O
influenza	other-disease
virus	other-disease
A	other-disease
in	O
1976	O
.	O

The	O
inappropriate	O
activity	O
of	O
aggrecanase	O
is	O
a	O
mechanism	O
by	O
which	O
cartilage	other-disease
degradation	other-disease
occurs	O
in	O
diseases	O
such	O
as	O
arthritis	other-disease
.	O

Neuropathic	other-disease
itch	other-disease
can	O
originate	O
at	O
any	O
point	O
along	O
the	O
afferent	O
pathway	O
as	O
a	O
result	O
of	O
damage	O
of	O
the	O
nervous	O
system	O
.	O

Several	O
techniques	O
and	O
types	O
of	O
catheter	O
are	O
available	O
,	O
including	O
sterile	O
(	O
single-use	O
)	O
and	O
clean	O
(	O
multiple	O
use	O
)	O
catheters	O
,	O
but	O
,	O
based	O
on	O
current	O
information	O
,	O
none	O
is	O
superior	O
to	O
others	O
in	O
reducing	O
the	O
incidence	O
of	O
urinary	other-disease
tract	other-disease
infection	other-disease
.	O

The	O
diseases	O
also	O
causes	O
a	O
reduction	O
in	O
the	O
maturation	O
of	O
erythroblasts	O
to	O
circulating	O
red	O
blood	O
cells	O
and	O
,	O
consequently	O
,	O
mild	O
anemia	other-disease
.	O

In	O
2006	O
,	O
flood	O
damage	O
from	O
Tropical	other-disease
Storm	other-disease
Ernesto	other-disease
caused	O
the	O
earthen	O
retaining	O
dam	O
which	O
formed	O
the	O
lake	O
to	O
burst	O
and	O
empty	O
.	O

Obsessive-compulsive	other-disease
disorder	other-disease
involves	O
unwanted	O
thoughts	O
or	O
images	O
that	O
are	O
unsettling	O
or	O
interfere	O
with	O
an	O
individual	O
's	O
life	O
,	O
followed	O
by	O
actions	O
that	O
temporarily	O
relieve	O
the	O
anxiety	O
caused	O
by	O
the	O
obsessions	O
(	O
APA	O
2000	O
)	O
.	O

A	other-disease
Hepatitis	other-disease
E-like	other-disease
virus	other-disease
has	O
been	O
isolated	O
from	O
a	O
Swedish	O
moose	O
.	O

Sarcoidosis	other-disease
is	O
a	O
systemic	O
inflammatory	O
disease	O
that	O
can	O
affect	O
any	O
organ	O
,	O
although	O
it	O
can	O
be	O
asymptomatic	O
and	O
is	O
discovered	O
by	O
accident	O
in	O
about	O
5	O
%	O
of	O
cases	O
.	O

Epileptic	other-disease
and	O
migraine	other-disease
auras	other-disease
are	O
due	O
to	O
the	O
involvement	O
of	O
specific	O
areas	O
of	O
the	O
brain	O
,	O
which	O
are	O
those	O
that	O
determine	O
the	O
symptoms	O
of	O
the	O
aura	O
.	O

They	O
were	O
set	O
to	O
on	O
Northwestern	O
State	O
in	O
the	O
second	O
round	O
of	O
the	O
Southland	O
Tournament	O
until	O
the	O
tournament	O
was	O
cancelled	O
amid	O
the	O
COVID-19	other-disease
pandemic	O
.	O

Patients	O
with	O
CFS	other-disease
,	O
like	O
those	O
with	O
neuromyotonia	other-disease
,	O
may	O
also	O
experience	O
paresthesias	O
.	O

Pulmonary	other-disease
fibrosis	O
involves	O
gradual	O
exchange	O
of	O
normal	O
lung	O
parenchyma	O
with	O
fibrotic	O
tissue	O
.	O

Rheumatic	other-disease
fever	other-disease
does	O
not	O
appear	O
to	O
be	O
related	O
.	O

X-linked	other-disease
thrombocytopenia	other-disease
is	O
considered	O
to	O
be	O
the	O
milder	O
phenotype	O
of	O
the	O
``	O
WAS	O
''	O
-related	O
disorders	O
.	O

Prominent	O
trinucleotide	other-disease
repeat	other-disease
disorders	other-disease
include	O
Fragile	other-disease
X	other-disease
syndrome	other-disease
and	O
Huntington	O
's	O
disease	O
.	O

In	O
its	O
broader	O
sense	O
,	O
``	O
ear	O
hair	O
''	O
may	O
also	O
include	O
the	O
fine	O
vellus	O
hair	O
covering	O
much	O
of	O
the	O
ear	O
,	O
particularly	O
at	O
the	O
prominent	O
parts	O
of	O
the	O
anterior	O
ear	O
,	O
or	O
even	O
the	O
abnormal	O
hair	O
growth	O
as	O
seen	O
in	O
hypertrichosis	other-disease
and	O
hirsutism	other-disease
.	O

It	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
Wilson	other-disease
's	O
disease	O
in	O
adults	O
,	O
adolescents	O
and	O
children	O
five	O
years	O
of	O
age	O
or	O
older	O
who	O
are	O
intolerant	other-disease
to	other-disease
D-penicillamine	other-disease
therapy	O
.	O

A	O
brief	O
episode	O
of	O
ischemia	O
affecting	O
the	O
brain	O
is	O
called	O
a	O
transient	other-disease
ischemic	other-disease
attack	other-disease
(	O
TIA	other-disease
)	O
,	O
often	O
called	O
a	O
mini-stroke	other-disease
.	O

Tan	O
was	O
recognised	O
for	O
his	O
leadership	O
contributions	O
to	O
overcoming	O
the	O
Severe	other-disease
acute	other-disease
respiratory	other-disease
syndrome	other-disease
(	O
SARS	other-disease
)	O
epidemic	O
in	O
2003	O
,	O
while	O
serving	O
as	O
the	O
Director	O
of	O
Medical	O
Services	O
in	O
Ministry	O
of	O
Health	O
(	O
MOH	O
)	O
from	O
2000	O
to	O
2004	O
.	O

In	O
the	O
older	O
generation	O
and	O
in	O
much	O
of	O
the	O
less-developed	O
world	O
,	O
valvular	O
disease	O
(	O
including	O
mitral	O
valve	O
prolapse	O
,	O
reinfection	O
in	O
the	O
form	O
of	O
valvular	O
endocarditis	O
,	O
and	O
valve	O
rupture	O
)	O
from	O
undertreated	O
rheumatic	other-disease
fever	other-disease
continues	O
to	O
be	O
a	O
problem	O
.	O

If	O
a	O
patient	O
scores	O
3	O
or	O
more	O
it	O
indicates	O
severe	O
pancreatitis	other-disease
and	O
the	O
patient	O
should	O
be	O
considered	O
for	O
transfer	O
to	O
ITU	O
.	O

He	O
was	O
born	O
with	O
Poliomyelitis	other-disease
(	O
polio	other-disease
)	O
.	O

Hyperthermia	other-disease
differs	O
from	O
fever	O
in	O
that	O
the	O
body	O
's	O
temperature	O
set	O
point	O
remains	O
unchanged	O
.	O

Many	O
dogs	O
and	O
cats	O
with	O
primary	O
adrenal	O
insufficiency	O
are	O
presented	O
in	O
Addisonian	other-disease
crisis	O
and	O
require	O
immediate	O
,	O
aggressive	O
therapy	O
.	O

Among	O
the	O
main	O
physical	O
health	O
problems	O
that	O
are	O
life-threatening	O
for	O
men	O
in	O
Australia	O
are	O
stroke	O
,	O
type	other-disease
2	other-disease
diabetes	other-disease
,	O
chronic	other-disease
lower	other-disease
respiratory	other-disease
disease	other-disease
,	O
blood	other-disease
and	other-disease
lymph	other-disease
cancer	other-disease
,	O
lung	other-disease
cancer	other-disease
,	O
prostate	other-disease
cancer	other-disease
and	O
colorectal	other-disease
cancer	other-disease
with	O
the	O
leading	O
cause	O
of	O
death	O
in	O
males	O
being	O
ischaemic	other-disease
heart	other-disease
disease	other-disease
.	O

The	O
Yellow	other-disease
Fever	other-disease
in	O
Buenos	O
Aires	O
was	O
a	O
series	O
of	O
epidemics	O
that	O
took	O
place	O
in	O
1852	O
,	O
1858	O
,	O
1870	O
and	O
1871	O
,	O
the	O
latter	O
being	O
a	O
disaster	O
that	O
killed	O
about	O
8	O
%	O
of	O
Porteños	O
:	O
in	O
a	O
city	O
where	O
the	O
daily	O
death	O
rate	O
was	O
less	O
than	O
20	O
,	O
there	O
were	O
days	O
that	O
killed	O
more	O
than	O
500	O
people	O
.	O

The	O
Tygerberg	O
scoring	O
system	O
helps	O
the	O
clinician	O
to	O
decide	O
whether	O
pericarditis	O
is	O
due	O
to	O
tuberculosis	O
or	O
whether	O
it	O
is	O
due	O
to	O
another	O
cause	O
:	O
night	O
sweats	O
(	O
1	O
point	O
)	O
,	O
weight	O
loss	O
(	O
1	O
point	O
)	O
,	O
fever	O
(	O
2	O
point	O
)	O
,	O
serum	O
globulin	O
&	O
gt	O
;	O
40g/l	O
(	O
3	O
points	O
)	O
,	O
blood	O
total	O
leucocyte	O
count	O
&	O
lt	O
;	O
10	O
x	O
109/l	O
(	O
3	O
points	O
)	O
;	O
a	O
total	O
score	O
of	O
6	O
or	O
more	O
is	O
highly	O
suggestive	O
of	O
tuberculous	other-disease
pericarditis	other-disease
.	O

In	O
2006	O
the	O
FDA	O
expended	O
approved	O
use	O
to	O
include	O
Dermatofibrosarcoma	other-disease
protuberans	other-disease
(	O
DFSP	other-disease
)	O
,	O
Myelodysplastic/myeloproliferative	other-disease
diseases	other-disease
(	O
MDS/MPD	other-disease
)	O
,	O
Aggressive	other-disease
systemic	other-disease
mastocytosis	other-disease
.	O

These	O
disorders	O
include	O
dwarfism	other-disease
,	O
Angelman	other-disease
syndrome	other-disease
,	O
and	O
various	O
metabolic	O
disorders	O
,	O
such	O
as	O
Tay-Sachs	other-disease
disease	other-disease
,	O
as	O
well	O
as	O
an	O
unusual	O
distribution	O
of	O
blood	O
types	O
.	O

It	O
includes	O
clubbed	other-disease
feet	other-disease
,	O
pulmonary	other-disease
hypoplasia	other-disease
and	O
cranial	other-disease
anomalies	other-disease
related	O
to	O
the	O
oligohydramnios	O
.	O

The	O
use	O
of	O
computed	O
tomography	O
scan	O
for	O
the	O
diagnosis	O
of	O
Wilms	other-disease
'	other-disease
tumor	other-disease
began	O
in	O
early	O
1970s	O
,	O
thanks	O
to	O
the	O
intuition	O
of	O
Dr.	O
Mario	O
Costici	O
,	O
an	O
Italian	O
physician	O
.	O

The	O
initial	O
Google	O
paper	O
stated	O
that	O
the	O
Google	O
Flu	other-disease
Trends	O
predictions	O
were	O
97	O
%	O
accurate	O
comparing	O
with	O
CDC	O
data	O
.	O

By	O
2007	O
,	O
GW501516	O
had	O
completed	O
two	O
phase	O
II	O
clinical	O
studies	O
and	O
other	O
studies	O
relating	O
to	O
obesity	other-disease
,	O
diabetes	other-disease
,	O
dyslipidemia	other-disease
and	O
cardiovascular	other-disease
disease	other-disease
,	O
but	O
GSK	O
abandoned	O
further	O
development	O
of	O
the	O
drug	O
in	O
2007	O
for	O
reasons	O
which	O
were	O
not	O
disclosed	O
at	O
the	O
time	O
.	O

The	O
incidence	O
of	O
PAIS	other-disease
is	O
estimated	O
to	O
be	O
one	O
in	O
130,000	O
.	O

Dwarfism	other-disease
can	O
result	O
from	O
many	O
medical	O
conditions	O
,	O
each	O
with	O
its	O
own	O
separate	O
symptoms	O
and	O
causes	O
.	O

caused	O
by	O
gene	O
deletion	O
)	O
results	O
in	O
HNPP	other-disease
.	O

Like	O
serotonin	O
,	O
an	O
imbalance	O
of	O
norepinephrine	O
may	O
also	O
result	O
in	O
depression	other-disease
.	O

Allergies	other-disease
,	O
exposure	O
to	O
environmental	O
irritants	O
,	O
or	O
a	O
persistent	O
inflammation	O
within	O
the	O
sinuses	O
can	O
lead	O
to	O
turbinate	other-disease
swelling	other-disease
.	O

Australian	O
astrophysicist	O
Rodney	O
Marks	O
had	O
Tourette	other-disease
syndrome	O
.	O

In	O
1980	O
,	O
Thomas	O
completed	O
a	O
fellowship	O
at	O
the	O
University	O
of	O
Maryland	O
Medical	O
Center	O
in	O
Baltimore	O
in	O
the	O
shock	other-disease
trauma	other-disease
unit	O
.	O

The	O
child	O
may	O
develop	O
congenital	other-disease
heart	other-disease
disease	other-disease
,	O
growth	other-disease
retardation	other-disease
,	O
microcephaly	other-disease
and	O
intellectual	other-disease
disability	other-disease
as	O
a	O
result	O
.	O

Sickle	other-disease
cell	other-disease
anemia	other-disease
is	O
a	O
pleiotropic	O
disease	O
because	O
the	O
expression	O
of	O
a	O
single	O
mutated	O
HBB	O
gene	O
produces	O
numerous	O
consequences	O
throughout	O
the	O
body	O
.	O

In	O
1998	O
,	O
Madredeus	O
contributed	O
``	O
Os	O
Dias	O
São	O
A	O
Noite	O
(	O
Suso	O
Saiz	O
Remix	O
)	O
''	O
to	O
the	O
AIDS	other-disease
benefit	O
compilation	O
album	O
``	O
''	O
produced	O
by	O
the	O
Red	O
Hot	O
Organization	O
.	O

However	O
,	O
the	O
grinding	O
process	O
produced	O
a	O
fine	O
siliceous	O
dust	O
,	O
that	O
after	O
adhering	O
to	O
the	O
workers	O
lungs	O
resulted	O
in	O
cases	O
of	O
silicosis	O
,	O
similar	O
to	O
the	O
condition	O
of	O
pneumoconiosis	other-disease
suffered	O
by	O
coal	O
miners	O
.	O

Lactic	other-disease
acidosis	other-disease
can	O
result	O
from	O
increased	O
anaerobic	O
metabolism	O
.	O

They	O
can	O
go	O
through	O
computed	O
tomography	O
(	O
CT	O
)	O
or	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
.The	O
classification	O
for	O
the	O
severity	O
of	O
MERRF	other-disease
syndrome	O
is	O
difficult	O
to	O
distinguish	O
since	O
most	O
individuals	O
will	O
exhibit	O
multi-symptoms	O
.	O

Wallace	O
died	O
from	O
pneumonia	other-disease
and	O
sepsis	other-disease
on	O
October	O
25	O
,	O
2013	O
,	O
aged	O
70	O
,	O
a	O
week	O
before	O
her	O
71st	O
birthday	O
.	O

The	O
drug	O
was	O
prescribed	O
to	O
promote	O
muscle	O
regrowth	O
in	O
disorders	O
which	O
cause	O
involuntary	O
weight	O
loss	O
,	O
and	O
is	O
used	O
as	O
part	O
of	O
treatment	O
for	O
HIV	other-disease
/	O
AIDS	other-disease
.	O

One	O
of	O
the	O
basic	O
techniques	O
of	O
cataract	other-disease
nucleofractis	O
(	O
fragmentation	O
and	O
removal	O
)	O
,	O
divide	O
and	O
conquer	O
is	O
among	O
the	O
safest	O
approaches	O
to	O
phacoemulsification	O
and	O
cataract	other-disease
removal	O
.	O

In	O
1865	O
the	O
Kingdom	O
legislature	O
passed	O
a	O
law	O
to	O
try	O
to	O
prevent	O
transmission	O
of	O
leprosy	other-disease
,	O
now	O
known	O
as	O
Hansen	other-disease
's	other-disease
disease	other-disease
after	O
the	O
scientist	O
who	O
discovered	O
the	O
bacterium	O
.	O

A	O
sentinel	O
loop	O
is	O
a	O
sign	O
seen	O
on	O
a	O
radiograph	O
that	O
indicates	O
localized	other-disease
ileus	other-disease
from	O
nearby	O
inflammation	O
.	O

The	O
gastroduodenal	O
artery	O
can	O
be	O
the	O
source	O
of	O
a	O
significant	O
gastrointestinal	O
bleed	O
,	O
which	O
may	O
arise	O
as	O
a	O
complication	O
of	O
peptic	other-disease
ulcer	other-disease
disease	other-disease
.	O

It	O
offers	O
potential	O
as	O
a	O
new	O
class	O
of	O
oral	O
direct-acting	O
antiviral	O
drug	O
for	O
Hepatitis	other-disease
C	other-disease
that	O
may	O
be	O
used	O
in	O
combination	O
with	O
either	O
current	O
treatment	O
strategies	O
or	O
with	O
new	O
classes	O
of	O
direct-acting	O
antiviral	O
drugs	O
in	O
development	O
.	O

Signs	O
of	O
genital	O
TVT	other-disease
include	O
a	O
discharge	O
from	O
the	O
prepuce	O
and	O
in	O
some	O
cases	O
urinary	O
retention	O
caused	O
by	O
blockage	O
of	O
the	O
urethra	O
.	O

Persons	O
with	O
self-limiting	other-disease
infection	other-disease
clear	O
the	O
infection	O
spontaneously	O
within	O
weeks	O
to	O
months	O
.	O

He	O
has	O
also	O
investigated	O
the	O
regulation	O
of	O
ACE2	O
,	O
the	O
receptor	O
for	O
SARS-CoV-2	other-disease
.	O

Mutations	O
in	O
the	O
gene	O
can	O
lead	O
to	O
a	O
defective	O
protein	O
and	O
several	O
forms	O
of	O
inherited	O
arrhythmias	other-disease
as	O
Long	other-disease
QT	other-disease
syndrome	other-disease
which	O
is	O
a	O
prolongation	O
of	O
the	O
QT	O
interval	O
of	O
heart	O
repolarization	O
,	O
Short	other-disease
QT	other-disease
syndrome	other-disease
,	O
and	O
Familial	other-disease
Atrial	other-disease
Fibrillation	other-disease
.	O

A	O
study	O
using	O
identical	O
and	O
fraternal	O
twins	O
indicated	O
that	O
there	O
is	O
a	O
stronger	O
likelihood	O
of	O
identical	O
twins	O
both	O
having	O
depression	other-disease
than	O
fraternal	O
twins	O
.	O

A	O
bi-annual	O
meeting	O
is	O
held	O
in	O
Geneva	O
to	O
bring	O
researcher	O
institutions	O
,	O
nongovernmental	O
agencies	O
,	O
and	O
representatives	O
from	O
countries	O
with	O
Buruli	other-disease
ulcer	other-disease
together	O
.	O

Smallpox	other-disease
was	O
only	O
the	O
first	O
epidemic	O
.	O

On	O
average	O
20	O
%	O
of	O
American	O
ESRD	other-disease
patients	O
die	O
annually	O
,	O
which	O
is	O
more	O
than	O
twice	O
that	O
of	O
Japan	O
.	O

A	O
genetic	O
disorder	O
causing	O
multiple	other-disease
cysts	other-disease
to	O
form	O
in	O
the	O
liver	O
tissue	O
,	O
usually	O
in	O
later	O
life	O
,	O
and	O
usually	O
asymptomatic	O
,	O
is	O
polycystic	O
liver	O
disease	O
.	O

About	O
10	O
%	O
of	O
people	O
with	O
hyperuricemia	other-disease
develop	O
gout	O
at	O
some	O
point	O
in	O
their	O
lifetimes	O
.	O

A	O
visual	O
examination	O
of	O
Chopin	O
's	O
preserved	O
heart	O
(	O
the	O
jar	O
was	O
not	O
opened	O
)	O
,	O
conducted	O
in	O
2014	O
and	O
first	O
published	O
in	O
the	O
American	O
Journal	O
of	O
Medicine	O
in	O
2017	O
,	O
suggested	O
that	O
the	O
likely	O
cause	O
of	O
his	O
death	O
was	O
a	O
rare	O
case	O
of	O
pericarditis	other-disease
caused	O
by	O
complications	O
of	O
chronic	other-disease
tuberculosis	other-disease
.	O

Schistosomiasis	other-disease
is	O
an	O
infectious	O
disease	O
from	O
freshwater	O
parasites	O
,	O
carried	O
by	O
snails	O
.	O

Rates	O
of	O
schizotypal	other-disease
personality	other-disease
disorder	other-disease
are	O
much	O
higher	O
in	O
relatives	O
of	O
individuals	O
with	O
schizophrenia	other-disease
than	O
in	O
the	O
relatives	O
of	O
people	O
with	O
other	O
mental	O
illnesses	O
or	O
in	O
people	O
without	O
mentally	O
ill	O
relatives	O
.	O

In	O
low-flow	O
(	O
ischemic	O
)	O
priapism	other-disease
the	O
flow	O
in	O
the	O
cavernous	O
arteries	O
is	O
reduced	O
or	O
absent	O
.	O

He	O
was	O
a	O
Christian	O
Scientist	O
and	O
Sean	O
Ely	O
believed	O
his	O
father	O
suffered	O
from	O
skin	other-disease
cancer	other-disease
.	O

Subluxation	other-disease
of	O
a	O
prosthesis	O
is	O
a	O
complication	O
where	O
the	O
prosthesis	O
is	O
mobile	O
and	O
is	O
partially	O
dislocated	O
.	O